

Development and validation of a predictive model for c thrombosis

Blood

111, 4902-4907

DOI: 10.1182/blood-2007-10-116327

Citation Report

#	ARTICLE	IF	CITATIONS
1	February 11, 1964. Clin-Alert, 1964, 2, 11-13.	0.0	1
2	Targeting patients for anticoagulant prophylaxis trials in patients with cancer: Who is at highest risk?. Thrombosis Research, 2007, 120, S29-S40.	1.7	42
3	Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?. Supportive Care in Cancer, 2008, 16, 1333-1341.	2.2	23
4	Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety, 2008, 17, i.	1.9	0
5	Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. British Journal of Haematology, 2008, 141, 587-597.	2.5	36
6	Diagnosing, Treating, and Preventing Venous Thromboembolism in Patients With Cancer. Clinical Journal of Oncology Nursing, 2008, 12, 869-874.	0.6	3
7	Chemotherapy-Induced Thrombosis: A Role for Microparticles and Tissue Factor?. Seminars in Thrombosis and Hemostasis, 2008, 34, 199-203.	2.7	38
8	Predictors of Venous Thromboembolism in Patients with Advanced Common Solid Cancers. Journal of Cancer Epidemiology, 2009, 2009, 1-9.	1.1	26
9	Examining the Involvement of Erythropoiesis-Stimulating Agents in Tumor Proliferation (Erythropoietin Receptors, Receptor Binding, Signal Transduction), Angiogenesis, and Venous Thromboembolic Events. Oncologist, 2009, 14, 34-42.	3.7	39
10	New Insights Into Cancer-Associated Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 316-320.	2.4	70
11	Venous Thromboembolism and Port-Related Thrombosis in Metastatic Colorectal Cancer Patients: A Monocenter Experience. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2010, 37, 30-34.	0.3	6
12	Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. Journal of Clinical Oncology, 2009, 27, 3786-3793.	1.6	155
13	Preventing Venous Thromboembolism in Cancer Patients: Can We Do Better?. Journal of Oncology Practice, 2009, 5, 165-166.	2.5	1
14	An Overview of the NCCN and ASCO Guidelines on Cancer-Associated Venous Thromboembolism. Cancer Investigation, 2009, 27, 41-52.	1.3	4
15	High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 2176-2181.	2.4	139
16	Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations. Annals of Oncology, 2009, 20, iv182-iv184.	1.2	41
17	D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology, 2009, 27, 4124-4129.	1.6	343
18	Cancer, Clots and Consensus: New Understanding of an Old Problem. Journal of Clinical Oncology, 2009, 27, 4821-4826.	1.6	149

#	ARTICLE	IF	CITATIONS
19	Cancer and thrombosis: implications of published guidelines for clinical practice. <i>Annals of Oncology</i> , 2009, 20, 1619-1630.	1.2	101
20	Venous Thromboembolism (VTE) in Patients with Cancer: Epidemiology and Risk Factors. <i>Cancer Investigation</i> , 2009, 27, 63-74.	1.3	150
21	Management of Venous Thromboembolism and the Potential to Impact Overall Survival in Patients with Cancer. <i>Pharmacotherapy</i> , 2009, 29, 1344-1356.	2.6	5
22	Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: The M. D. Anderson Cancer Center experience. <i>American Journal of Hematology</i> , 2009, 84, 408-413.	4.1	14
23	Venous thromboembolism and nonsmall cell lung cancer. <i>Cancer</i> , 2009, 115, 5516-5525.	4.1	72
24	Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. <i>Cancer</i> , 2009, 115, 5637-5650.	4.1	31
26	Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 171-181.	3.8	156
27	Upper vs. lower extremity deep vein thrombosis: outcome definitions of venous thromboembolism for clinical predictor rules or risk factor analyses in hospitalized patients. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1041-1042.	3.8	21
29	Epidemiology of cancer-related venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 9-23.	1.7	193
30	Risk stratification for cancer-associated venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 35-47.	1.7	35
31	Procoagulant mechanisms in tumour cells. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 49-60.	1.7	146
32	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. <i>Advances in Hematology</i> , 2009, 2009, 1-5.	1.0	14
34	Cancer and Thrombosis: Back to the Future<i>Renewed Interest in an Old Problem</i>. <i>Cancer Investigation</i> , 2009, 27, 472-473.	1.3	8
35	The Incidence and Risk of Venous Thromboembolism Associated With Cancer and Nonsurgical Cancer Treatment. <i>Cancer Investigation</i> , 2009, 27, 105-115.	1.3	51
36	Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. <i>Thrombosis Research</i> , 2009, 123, S18-S21.	1.7	64
37	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncology</i> , The, 2009, 10, 943-949.	10.7	538
38	A step in the right direction, but one size might not fit all. <i>Lancet Oncology</i> , The, 2009, 10, 930-931.	10.7	7
39	Assessing Risk of Venous Thromboembolism in the Patient With Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4839-4847.	1.6	446

#	ARTICLE	IF	CITATIONS
40	Venous Thromboembolism Prophylaxis and Treatment in Cancer: A Consensus Statement of Major Guidelines Panels and Call to Action. <i>Journal of Clinical Oncology</i> , 2009, 27, 4919-4926.	1.6	162
41	Cancer-associated thrombosis. <i>Current Opinion in Hematology</i> , 2009, 16, 378-385.	2.5	22
42	Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. <i>Blood</i> , 2009, 113, 3911-3917.	1.4	141
43	The role of thromboprophylaxis in cancer patients: emerging data. <i>Current Opinion in Hematology</i> , 2010, 17, 450-456.	2.5	9
44	Risk assessment of venous thromboembolism in hospitalized medical patients. <i>Current Opinion in Pulmonary Medicine</i> , 2010, 16, 419-425.	2.6	17
45	Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1049-1054.	3.4	87
46	Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. <i>Blood</i> , 2010, 115, 5322-5328.	1.4	101
47	Prediction of venous thromboembolism in cancer patients. <i>Blood</i> , 2010, 116, 5377-5382.	1.4	643
48	En route to personalized prophylaxis. <i>Blood</i> , 2010, 116, 5085-5086.	1.4	0
49	Aortic thrombosis resolved with enoxaparin in a patient treated with cisplatin-based regimen for small cell lung cancer. <i>International Journal of Hematology</i> , 2010, 91, 892-896.	1.6	12
51	Venous thromboembolism and cancer: a systematic review. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 67-78.	2.1	40
52	Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 286-293.	2.1	17
54	The potential benefits of low-molecular-weight heparins in cancer patients. <i>Journal of Hematology and Oncology</i> , 2010, 3, 3.	17.0	35
55	High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 114-120.	3.8	195
56	Venous thromboembolism in malignant gliomas. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 221-227.	3.8	122
57	Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1702-1709.	3.8	37
58	PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1959-1965.	3.8	211
59	Risk factors for cancer-associated venous thromboembolism in outpatient deep venous thrombosis clinics. <i>British Journal of Haematology</i> , 2010, 150, 640-641.	2.5	1

#	ARTICLE	IF	CITATIONS
60	Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1228-1232.	3.4	17
61	Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. <i>Thrombosis and Haemostasis</i> , 2010, 103, 338-343.	3.4	84
62	Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. <i>Annals of Oncology</i> , 2010, 21, v274-v276.	1.2	52
63	Venous Thromboembolism in Patients With Cancer. <i>Journal of Pharmacy Practice</i> , 2010, 23, 294-302.	1.0	1
64	D-dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecologic cancer. <i>Annals of Oncology</i> , 2010, 21, 1651-1656.	1.2	37
65	Thrombosis in Cancer: An Update on Prevention, Treatment, and Survival Benefits of Anticoagulants. Hematology American Society of Hematology Education Program, 2010, 2010, 144-149.	2.5	52
66	Issues in assessing and reducing the risk for venous thromboembolism. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, S9-S16.	1.0	4
67	Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWISS Venous ThromboEmbolic Registry (SWIVTER). <i>Annals of Oncology</i> , 2010, 21, 931-935.	1.2	34
68	Venous thromboembolism risk factor assessment and prophylaxis. <i>Phlebology</i> , 2010, 25, 219-223.	1.2	22
69	The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. <i>Thrombosis Research</i> , 2010, 125, 216-219.	1.7	20
70	Venous thromboembolism and prognosis in cancer. <i>Thrombosis Research</i> , 2010, 125, 490-493.	1.7	319
71	Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. <i>Thrombosis Research</i> , 2010, 126, 113-118.	1.7	115
72	Incidence and Risk Factors of Venous Thromboembolic Events in Lymphoma. <i>American Journal of Medicine</i> , 2010, 123, 935-941.	1.5	43
73	Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. <i>Thrombosis Research</i> , 2010, 125, S1-S7.	1.7	82
74	Tests predictive of thrombosis in cancer. <i>Thrombosis Research</i> , 2010, 125, S12-S15.	1.7	26
75	Thromboprophylaxis during chemotherapy in patients with advanced cancer. <i>Thrombosis Research</i> , 2010, 125, S17-S20.	1.7	16
76	Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. <i>Thrombosis Research</i> , 2010, 125, S96-S102.	1.7	40
77	Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management. <i>Thrombosis Research</i> , 2010, 125, S117-S119.	1.7	39

#	ARTICLE	IF	CITATIONS
78	Prevention and treatment of venous thromboembolism among patients with cancer: The American Society of Clinical Oncology Guidelines. Thrombosis Research, 2010, 125, S120-S127.	1.7	38
79	The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thrombosis Research, 2010, 125, S128-S133.	1.7	69
80	Cancer-Associated Thrombosis. Hematology/Oncology Clinics of North America, 2010, 24, 695-707.	2.2	6
82	Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 2011, 22, vi85-vi92.	1.2	439
83	Supportive care in neurooncology. Revue Neurologique, 2011, 167, 762-772.	1.5	5
86	Cancer-associated thrombosis: an update. Drug Discovery Today Disease Mechanisms, 2011, 8, e39-e45.	0.8	4
88	Arterial thrombosis in ambulatory cancer patients treated with chemotherapy. Thrombosis Research, 2011, 127, 382-383.	1.7	46
90	Thrombosis and malignant hemopathies: truths and realities. Hematologie, 2011, 17, 183-188.	0.0	0
91	Thrombosis in cancer. , 2011, , 274-282.		1
92	Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Related Outcome Measures, 2011, 2, 175.	1.2	15
93	An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients. Thrombosis and Haemostasis, 2011, 105, 931-932.	3.4	20
94	Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome – a comprehensive cancer center experience. Vascular Health and Risk Management, 2011, Volume 7, 153-158.	2.3	57
95	Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. Chest, 2011, 140, 706-714.	0.8	401
96	Risk Assessment and Prophylaxis for VTE in Cancer Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 789-797.	4.9	37
97	Venous Thromboembolic Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 714-777.	4.9	108
98	Management of venous thromboembolism in patients with cancer. Journal of Thrombosis and Haemostasis, 2011, 9, 316-324.	3.8	85
99	The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer. Breast, 2011, 20, 151-154.	2.2	8
100	Prediction of Venous Thromboembolism in Patients With Cancer by Measuring Thrombin Generation: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology, 2011, 29, 2099-2103.	1.6	196

#	ARTICLE	IF	CITATIONS
101	The eighth American college of chest physicians guidelines on venous thromboembolism prevention: implications for hospital prophylaxis strategies. Journal of Thrombosis and Thrombolysis, 2011, 31, 196-208.	2.1	18
102	Venous thromboembolism (VTE) in hospitalized cancer patients: prophylaxis failure or failure to prophylax!. Journal of Thrombosis and Thrombolysis, 2011, 31, 107-112.	2.1	16
103	Anticoagulation in the management of venous thromboembolism in the cancer patient. Journal of Thrombosis and Thrombolysis, 2011, 31, 282-294.	2.1	15
104	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis, 2011, 32, 242-266.	2.1	2
105	SEOM guidelines on thrombosis in cancer patients. Clinical and Translational Oncology, 2011, 13, 592-596.	2.4	5
106	Prevention of venous thromboembolism in cancer patients: current approaches and opportunities for improvement. Oncology Reviews, 2011, 5, 191-204.	1.8	1
107	Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. Journal of Translational Medicine, 2011, 9, 179.	4.4	90
108	Venous thromboembolism in the patient with cancer. Cancer, 2011, 117, 1334-1349.	4.1	158
109	Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer, 2011, 117, 3860-3866.	4.1	71
110	Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer. Cancer, 2011, 117, 3641-3649.	4.1	16
112	Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Annals of Oncology, 2011, 22, 2394-2402.	1.2	19
113	Venous Thromboembolism Prophylaxis After Hospital Discharge: Transition to Preventive Care. Hospital Practice (1995), 2011, 39, 7-15.	1.0	6
114	Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ: British Medical Journal, 2011, 343, d4656-d4656.	2.3	113
115	Microparticles in Hemostasis and Thrombosis. Circulation Research, 2011, 108, 1284-1297.	4.5	717
116	High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis. Journal of Clinical Oncology, 2011, 29, 3466-3473.	1.6	369
117	Anticoagulant use in cancer patients. Expert Opinion on Pharmacotherapy, 2011, 12, 351-362.	1.8	1
118	Optimising management of cancer related anemia. Indian Journal of Cancer, 2011, 48, 1.	0.2	4
119	Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism. Circulation, 2012, 126, 448-454.	1.6	179

#	ARTICLE	IF	CITATIONS
120	Prevention and treatment of venous thromboembolism in patients with cancer. Therapeutic Advances in Hematology, 2012, 3, 45-58.	2.5	9
121	Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2012, 30, 4416-4426.	1.6	197
122	Thrombosis and acute leukemia. Hematology, 2012, 17, s169-s173.	1.5	12
123	Impact of Venous Thromboembolism on Mortality of Elderly Medicare Patients with Stage III Colon Cancer. Oncologist, 2012, 17, 1191-1197.	3.7	16
124	Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study. Journal of Clinical Oncology, 2012, 30, 3870-3875.	1.6	110
125	Venous thromboembolism in the hematologic malignancies. Current Opinion in Oncology, 2012, 24, 702-710.	2.4	55
126	Thromboprophylaxis Guidelines in Cancer with a Primary Focus on Ambulatory Patients Receiving Chemotherapy: A Review from the Southern Network on Adverse Reactions (SONAR). Seminars in Thrombosis and Hemostasis, 2012, 38, 759-767.	2.7	24
128	Inherited and Acquired Risk Factors for Venous Thromboembolism. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 127-137.	2.1	17
129	D-Dimer Assays in Diagnosis and Management of Thrombotic and Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2012, 38, 673-682.	2.7	97
130	Thrombosis: simplified. Phlebology, 2012, 27, 12-22.	1.2	1
131	Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. British Journal of Cancer, 2012, 107, 1244-1248.	6.4	36
132	Comparative Effectiveness Research, Genomics-Enabled Personalized Medicine, and Rapid Learning Health Care: A Common Bond. Journal of Clinical Oncology, 2012, 30, 4233-4242.	1.6	44
133	Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the "SENDO experience"™. Annals of Oncology, 2012, 23, 1416-1421.	1.2	78
134	Predicting and accounting for VTE in phase I cancer studies. Annals of Oncology, 2012, 23, 1373-1375.	1.2	1
135	Venous Thromboembolism in Cancer Patients Undergoing Major Abdominal Surgery: Prevention and Management. ISRN Vascular Medicine, 2012, 2012, 1-22.	0.7	10
136	Do circulating tumor cells play a role in coagulation and thrombosis?. Frontiers in Oncology, 2012, 2, 115.	2.8	27
137	Chemotherapy-Related Thrombocytosis: Does It Increase the Risk of Thromboembolism?. Oncology, 2012, 82, 327-332.	1.9	11
138	Venous thrombosis in the patient with cancer. Southern African Journal of Gynaecological Oncology, 2012, 4, 50-54.	0.3	0

#	ARTICLE	IF	CITATIONS
140	A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. <i>Thrombosis and Haemostasis</i> , 2012, 108, 225-235.	3.4	88
141	Acquired activated protein C resistance in sarcoma patients. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 428-433.	1.0	2
143	Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 835-846.	4.9	19
144	Preventing VTE in Outpatients With Cancer: Response. <i>Chest</i> , 2012, 142, 266-267.	0.8	0
145	How I manage venous thromboembolism risk in hospitalized medical patients. <i>Blood</i> , 2012, 120, 1562-1569.	1.4	23
146	Cancer and contraception. <i>Contraception</i> , 2012, 86, 191-198.	1.5	76
147	Venous thromboembolism in cancer patients – Risk scores and recent randomised controlled trials. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1042-1048.	3.4	58
148	Preventing venous thromboembolism in hospitalized patients with cancer: Improving compliance with clinical practice guidelines. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 469-481.	1.0	22
149	Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. <i>Blood</i> , 2012, 119, 5543-5552.	1.4	176
150	Treating venous thromboembolism in patients with cancer. <i>Expert Review of Hematology</i> , 2012, 5, 201-209.	2.2	25
151	Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. <i>Thrombosis Research</i> , 2012, 129, S6-S9.	1.7	36
152	Risk assessment for cancer-associated thrombosis: What is the best approach?. <i>Thrombosis Research</i> , 2012, 129, S10-S15.	1.7	35
153	Low-molecular-weight heparin and survival in lung cancer. <i>Thrombosis Research</i> , 2012, 129, S114-S118.	1.7	18
154	Thromboprophylaxis in non-surgical cancer patients. <i>Thrombosis Research</i> , 2012, 129, S137-S145.	1.7	14
155	Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients—a pilot study. <i>Supportive Care in Cancer</i> , 2012, 20, 2713-2720.	2.2	7
159	Thromboembolic Events Before Esophagectomy for Esophageal Cancer Do Not Result in Worse Outcomes. <i>Annals of Thoracic Surgery</i> , 2012, 94, 1118-1125.	1.3	7
161	Adjuvant therapy in breast cancer and venous thromboembolism. <i>Thrombosis Research</i> , 2012, 130, S66-S70.	1.7	16
164	Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 601-609.	27.0	489

#	ARTICLE	IF	CITATIONS
165	Low-Molecular-Weight Heparin Versus Placebo for the Prevention of Venous Thromboembolism in Metastatic Breast Cancer or Stage III/IV Lung Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 159-165.	1.7	147
166	Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma. <i>Thrombosis Research</i> , 2012, 130, 7-11.	1.7	44
167	Risk assessment models for thromboprophylaxis of medical patients. <i>Thrombosis Research</i> , 2012, 129, 127-132.	1.7	32
168	Anticancer treatment and thrombosis. <i>Thrombosis Research</i> , 2012, 129, 353-359.	1.7	43
170	Thrombosis and cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 437-449.	27.6	126
171	Anticoagulants in cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2230-2241.	3.8	13
172	Clinical decision rules in venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 303-317.	1.7	9
173	Venous thromboembolism: Epidemiology and magnitude of the problem. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 235-242.	1.7	176
174	Novel High-Sensitive D-Dimer Determination Predicts Chemotherapy-Associated Venous Thromboembolism in Intermediate Risk Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2012, 13, 482-487.	2.6	48
175	Incidence and predictive factors of symptomatic thrombosis related to peripherally inserted central catheters in chemotherapy patients. <i>Thrombosis Research</i> , 2012, 130, 323-326.	1.7	89
176	The assessment of thrombotic risk using a predictive model in metastatic cancer patients undergoing first-line therapy. <i>Thrombosis Research</i> , 2012, 130, 967-970.	1.7	2
177	Monocyte count associated with subsequent symptomatic venous thromboembolism (VTE) in hospitalized patients with solid tumors. <i>Thrombosis Research</i> , 2012, 130, e279-e282.	1.7	5
178	Lung cancer associated venous thromboembolic disease: A comprehensive review. <i>Lung Cancer</i> , 2012, 75, 1-8.	2.0	54
181	Cancer-related venous thromboembolic disease: current management and areas of uncertainty. <i>Phlebology</i> , 2012, 27, 53-60.	1.2	4
182	Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. , 2012, , CD008500.		124
183	Asymptomatic Pulmonary Embolism in Lung Cancer: Prevalence and Analysis of Clinical and Radiological Characteristics in 141 Outpatients. <i>Tumori</i> , 2012, 98, 594-600.	1.1	12
184	Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?. <i>Thrombosis</i> , 2012, 2012, 1-9.	1.4	12
185	Venous Thromboembolism Prophylaxis in Cancer Patients. , 2012, , .		1

#	ARTICLE	IF	CITATIONS
186	Cancer-associated thrombosis: updates and controversies. Hematology American Society of Hematology Education Program, 2012, 2012, 626-630.	2.5	57
187	Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie, 2012, 32, 115-125.	1.9	64
188	Ambulatory Patients with Metastatic or Locally Advanced Cancer: is Body Mass Index ≥ 35 A Risk Factor for Thromboembolism also in European Countries?. Annals of Oncology, 2012, 23, ix515.	1.2	0
189	Risk of venous thromboembolism and primary prophylaxis in cancer. Hamostaseologie, 2012, 32, 132-137.	1.9	16
190	Venous Thromboembolism in Cancer Patients. , 2012, , .		1
191	PrevenÃ§Ã£o do tromboembolismo na cirurgia do cÃncer do aparelho digestivo. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2012, 25, 216-223.	0.5	2
192	The use of weighted and scored risk assessment models for venous thromboembolism. Thrombosis and Haemostasis, 2012, 108, 1072-1076.	3.4	40
193	The Therapeutic Management of Bleeding and Thrombotic Disorders Complicating CNS Malignancies. Current Treatment Options in Oncology, 2012, 13, 451-464.	3.0	10
194	Clinical analysis of postoperative venous thromboembolism risk factors in lung cancer patients. Journal of Surgical Oncology, 2012, 106, 736-741.	1.7	51
195	Risk assessment models for cancer-associated venous thromboembolism. Cancer, 2012, 118, 3468-3476.	4.1	33
196	Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer, 2012, 118, 3053-3061.	4.1	85
197	Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. Journal of Thrombosis and Thrombolysis, 2012, 34, 143-163.	2.1	0
198	A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Internal and Emergency Medicine, 2012, 7, 291-292.	2.0	299
199	D-Dimer as a Potential Prognostic Marker. Pathology and Oncology Research, 2012, 18, 669-674.	1.9	23
200	Facteurs de risque et scores de la maladie thromboembolique veineuse. Option/Bio, 2012, 23, 17-18.	0.0	0
201	Venous thromboembolism and cancer. ANZ Journal of Surgery, 2012, 82, 294-298.	0.7	7
202	Cancer and coagulation. American Journal of Hematology, 2012, 87, S82-7.	4.1	68
203	Older renal cell cancer patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data. BMC Cancer, 2013, 13, 209.	2.6	4

#	ARTICLE	IF	CITATIONS
204	Thromboembolic disease in cancer patients. Supportive Care in Cancer, 2013, 21, 1481-1486.	2.2	3
205	Cancer-associated venous thromboembolism: risk assessment, prevention, and treatment. Memo - Magazine of European Medical Oncology, 2013, 6, 197-201.	0.5	1
206	Overview and assessment of risk factors for pulmonary embolism. Expert Review of Respiratory Medicine, 2013, 7, 171-191.	2.5	14
207	Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemotherapy and Pharmacology, 2013, 72, 65-73.	2.3	51
208	Targeted prophylaxis in cancer: the evidence accumulates. Internal and Emergency Medicine, 2013, 8, 187-189.	2.0	11
209	IL-6-174 G>C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine, 2013, 62, 64-69.	3.2	27
210	A retrospective cohort study of venous thromboembolism(VTE) in 1035 Japanese myeloma patients treated with thalidomide; lower incidence without statistically significant association between specific risk factors and development of VTE and effects of thromboprophylaxis with aspirin and warfarin. Thrombosis Research, 2013, 131, 140-144.	1.7	15
211	A prospective study on survival in cancer patients with and without venous thromboembolism. Internal and Emergency Medicine, 2014, 9, 559-67.	2.0	27
212	Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancer. Critical Reviews in Oncology/Hematology, 2013, 88, 1-18.	4.4	49
213	Epidemiology of cancer-associated venous thrombosis. Blood, 2013, 122, 1712-1723.	1.4	914
214	Biomarkers for prediction of venous thromboembolism in cancer. Blood, 2013, 122, 2011-2018.	1.4	208
215	Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review. Journal of Thrombosis and Thrombolysis, 2013, 35, 67-80.	2.1	39
216	Haemostatic challenges in the cancer patient: Focus on the perioperative period. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2013, 27, 493-511.	4.0	5
217	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 2189-2204.	1.6	717
218	Biomolecular markers of cancer-associated thromboembolism. Critical Reviews in Oncology/Hematology, 2013, 88, 19-29.	4.4	31
219	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2013, 87, 80-89.	4.4	63
220	The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE. Thrombosis Research, 2013, 131, e133-e140.	1.7	7
222	Incidence of venous thromboembolism in patients with cancer – A cohort study using linked United Kingdom databases. European Journal of Cancer, 2013, 49, 1404-1413.	2.8	380

#	ARTICLE	IF	CITATIONS
223	Predictive model of venous thromboembolism in endometrial cancer. Gynecologic Oncology, 2013, 128, 544-551.	1.4	55
225	Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec). Thrombosis and Haemostasis, 2013, 113, 1028-1034.	2.8	4314
226	Pulmonary Embolism and Deep Vein Thrombosis. , 2013, , 580-595.		1
227	Coagulation and cancer: biological and clinical aspects. Journal of Thrombosis and Haemostasis, 2013, 11, 223-233.	3.8	377
228	Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. British Journal of Haematology, 2013, 161, 764-777.	2.5	23
229	Cardioncology: State of the heart. International Journal of Cardiology, 2013, 168, 680-687.	1.7	69
230	Mechanisms of thrombosis in cancer. Thrombosis Research, 2013, 131, S59-S62.	1.7	94
231	Thromboprophylaxis in Ambulatory Lung Cancer Treatment. Clinical Journal of Oncology Nursing, 2013, 17, 74-79.	0.6	2
232	Microvesicles as risk markers for venous thrombosis. Expert Review of Hematology, 2013, 6, 91-101.	2.2	51
233	Thrombosis and Cancer. , 2013, , 408-422.		0
234	Thrombosis in pediatric cancer: identifying the risk factors to improve care. Expert Review of Hematology, 2013, 6, 599-609.	2.2	29
235	Assessing the Risk and Prognosis of Thrombotic Complications in Cancer Patients. Archives of Pathology and Laboratory Medicine, 2013, 137, 1286-1295.	2.5	41
236	Primary Venous Thromboembolism Prophylaxis in Ambulatory Cancer Patients. Annals of Pharmacotherapy, 2013, 47, 198-209.	1.9	8
237	Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer, 2013, 119, 648-655.	4.1	356
238	Prediction of venous thromboembolism after surgery for colorectal cancer: a prevention paradigm. Colorectal Cancer, 2013, 2, 233-242.	0.8	2
240	Comprehensive Update on the Prevention and Treatment of Venous Thromboembolism in Cancer Patients. Seminars in Thrombosis and Hemostasis, 2013, 39, 127-140.	2.7	12
241	Cancer and Venous Thrombosis: Current Comprehensions and Future Perspectives. Seminars in Thrombosis and Hemostasis, 2013, 39, 507-514.	2.7	13
242	TNF- α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. Annals of Oncology, 2013, 24, 2571-2575.	1.2	16

#	ARTICLE	IF	CITATIONS
243	Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 567-572.	1.0	16
244	Reply to T.H. Oo. <i>Journal of Clinical Oncology</i> , 2013, 31, 4381-4382.	1.6	3
245	Venous Thromboembolism and Cancer. <i>Circulation</i> , 2013, 128, 2614-2618.	1.6	33
246	Venous Thromboembolism in Hospitalized Patients With Active Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 469-475.	1.7	16
247	Patients With Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2013, 19, 172-176.	1.7	4
248	Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 724-730.	1.6	91
249	Thromboembolism during neoadjuvant therapy for rectal cancer: a systematic review. <i>Colorectal Disease</i> , 2013, 15, e496-502.	1.4	1
250	Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. <i>Acta Oncologica</i> , 2013, 52, 187-190.	1.8	12
251	Impact of chemotherapy on activated protein C–dependent thrombin generation—Association with VTE occurrence. <i>International Journal of Cancer</i> , 2013, 133, 1253-1258.	5.1	26
252	Increased Risk of Chemotherapy-Associated Venous Thromboembolism in Elderly Patients with Cancer. <i>Rejuvenation Research</i> , 2013, 16, 224-231.	1.8	22
253	Venous thrombosis risk assessment in medical inpatients: the medical inpatients and thrombosis (MITH) study. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 634-641.	3.8	40
254	Aging: an important risk factor in chemotherapy-associated vascular diseases. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 899-901.	2.4	4
255	Cancer-associated thrombosis. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 684-691.	2.5	72
256	Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. <i>Haematologica</i> , 2013, 98, 1309-1314.	3.5	65
257	Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients. <i>Blood</i> , 2013, 122, 1873-1880.	1.4	271
258	Impact of chemotherapy on venous thromboembolism: Comment to: Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. <i>Haematologica</i> , 2013, 98, e153-e154.	3.5	7
260	Evaluation of Risk Factors for Venous Thromboembolism in Chinese Women With Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 65-72.	2.5	13
261	Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. <i>Journal of Extracellular Vesicles</i> , 2013, 2, 19728.	12.2	24

#	ARTICLE	IF	CITATIONS
262	Venous Thromboembolic Events in Germ Cell Cancer Patients Undergoing Platinum-Based Chemotherapy. <i>Onkologie</i> , 2013, 36, 663-668.	0.8	21
263	Venous Thromboembolic Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1402-1429.	4.9	80
264	Venous Thromboembolism Prevention in Cancer Outpatients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1431-1438.	4.9	17
265	Risk Assessment for Venous Thromboembolism in Patients With Neuroepithelial Tumors: Pretreatment Score to Identify High Risk Patients. <i>Neurologia Medico-Chirurgica</i> , 2013, 53, 467-473.	2.2	5
266	Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 101.	1.9	107
267	Disappearance of a major thrombus in the brachiocephalic vein without anticoagulant therapy in a patient with seminoma - a case report. <i>Canadian Urological Association Journal</i> , 2013, 7, e241-3.	0.6	0
268	Guidelines concerning the management of venous thromboembolic diseases in cancer patients. <i>Sang Thrombose Vaisseaux</i> , 2013, 25, 132-138.	0.1	0
269	Platelet count and outcome in patients with acute venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1025-1034.	3.4	17
270	Thrombophilia. , 2013, , 205-239.		11
271	Deep Vein Thrombosis and Pulmonary Embolism. , 2013, , 247-261.		1
272	The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience. <i>Patient Preference and Adherence</i> , 2013, 7, 1111.	1.8	2
273	Supportive care of palliative chemotherapy for advanced stage lung cancer patients: Summary for the daily practice. <i>Journal of Nursing Education and Practice</i> , 2013, 4, .	0.2	1
274	Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The TromsÅ, Study. <i>PLoS ONE</i> , 2014, 9, e92011.	2.5	31
275	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>PLoS ONE</i> , 2014, 9, e111440.	2.5	64
276	Evidence-Based Guidance on Venous Thromboembolism in Patients with Solid Tumours. <i>Current Oncology</i> , 2014, 21, 504-514.	2.2	10
277	Predictors of Venous Thromboembolic Events Associated with Central Venous Port Insertion in Cancer Patients. <i>Journal of Oncology</i> , 2014, 2014, 1-6.	1.3	29
278	Cancer and Thrombosis. <i>Journal of Hematology & Thromboembolic Diseases</i> , 2014, 02, .	0.1	0
279	THE PROBLEM OF THE USE OF NEW ORAL ANTICOAGULANTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY. <i>Rational Pharmacotherapy in Cardiology</i> , 2014, 10, 634-639.	0.8	1

#	ARTICLE	IF	CITATIONS
281	Flamethrowers: blood cells and cancer thrombosis risk. Hematology American Society of Hematology Education Program, 2014, 2014, 410-417.	2.5	18
282	Prevalence and Associations of VTE in Patients With Newly Diagnosed Lung Cancer. Chest, 2014, 146, 650-658.	0.8	71
283	Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. Haematologica, 2014, 99, 1638-1644.	3.5	20
284	Enhancing Therapeutic Decision Making When Options Abound: Toxicities Matter. Journal of Clinical Oncology, 2014, 32, 1990-1993.	1.6	24
285	Pulmonary embolism and hematologic outcome in cancer patients initiating chemotherapy. Indian Journal of Cancer, 2014, 51, 303.	0.2	2
286	Prevention and treatment of venous thromboembolism in patients with cancer. Hematology American Society of Hematology Education Program, 2014, 2014, 312-317.	2.5	7
287	Risk Assessment for Thrombosis in Cancer. Seminars in Thrombosis and Hemostasis, 2014, 40, 319-324.	2.7	40
288	Cancer and Venous Thromboembolic Disease: From Molecular Mechanisms to Clinical Management. Current Oncology, 2014, 21, 134-143.	2.2	61
289	Adverse Impact of Venous Thromboembolism on Patients with Cancer. Seminars in Thrombosis and Hemostasis, 2014, 40, 313-318.	2.7	8
290	Venous Thromboembolism in Cancer Patients. Hospital Practice (1995), 2014, 42, 24-33.	1.0	8
291	Flamethrowers: blood cells and cancer thrombosis risk. Hematology American Society of Hematology Education Program, 2014, 2014, 410-417.	2.5	28
292	Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro-Oncology, 2014, 16, 1645-1651.	1.2	63
293	Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. , 2014, , CD008500.		38
294	Vascular Toxicity Associated With Chemotherapy and Molecular Targeted Therapy: What Should a Radiologist Know?. American Journal of Roentgenology, 2014, 203, 1353-1362.	2.2	14
295	Screening high-risk cancer patients for VTE: A prospective observational study. Thrombosis Research, 2014, 134, 1205-1207.	1.7	39
296	Iron deficiency alters megakaryopoiesis and platelet phenotype independent of thrombopoietin. American Journal of Hematology, 2014, 89, 524-529.	4.1	69
297	Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Thrombosis and Haemostasis, 2014, 111, 670-678.	3.4	88
298	Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability. BMC Cancer, 2014, 14, 991.	2.6	46

#	ARTICLE	IF	CITATIONS
299	The coagulopathy of cancer. <i>Current Opinion in Hematology</i> , 2014, 21, 423-429.	2.5	74
300	Thromboembolism During Neoadjuvant Therapy for Gastrointestinal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 627-634.	1.3	3
301	Thrombotic risk factors in patients undergoing chemotherapy via peripherally inserted central catheter. <i>Journal of International Medical Research</i> , 2014, 42, 863-869.	1.0	20
302	Cancer-Associated Thrombosis: An Overview. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S18991.	1.3	151
303	Estimated Glomerular Filtration Rate Is an Easy Predictor of Venous Thromboembolism in Cancer Patients Undergoing Platinum-Based Chemotherapy. <i>Oncologist</i> , 2014, 19, 562-567.	3.7	8
304	Venous Thromboembolism in Patients With Myeloma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 600-606.	1.7	14
305	Effects of Cancer on Platelets. <i>Seminars in Oncology</i> , 2014, 41, 311-318.	2.2	49
306	Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. <i>Thrombosis Research</i> , 2014, 134, 44-49.	1.7	28
307	Management of venous thromboembolism in cancer patients. <i>Reviews in Vascular Medicine</i> , 2014, 2, 24-36.	0.4	3
308	Thromboprophylaxis in Cancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 395-400.	2.7	7
310	Thromboprophylaxis for lung cancer patientsâ€”multimodality assessment of clinician practices, perceptions and decision support tools. <i>Supportive Care in Cancer</i> , 2014, 22, 1915-1922.	2.2	3
311	Clinical models and biochemical predictors of VTE in lung cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 771-789.	5.9	13
312	Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. <i>Blood Reviews</i> , 2014, 28, 1-8.	5.7	29
313	Phase 1 study of cetuximab in combination with 5â€¢fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. <i>Cancer</i> , 2014, 120, 454-456.	4.1	5
314	Reply to phase 1 study of cetuximab in combination with 5â€¢fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. <i>Cancer</i> , 2014, 120, 456-456.	4.1	1
315	Clinical guide SEOM on venous thromboembolism in cancer patients. <i>Clinical and Translational Oncology</i> , 2014, 16, 1079-1090.	2.4	25
316	Thromboembolic events in patients with urothelial carcinoma undergoing neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 975-980.	1.6	26
317	Prophylaxis against Venous Thromboembolism in Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 2515-2519.	27.0	44

#	ARTICLE	IF	CITATIONS
318	Statins are Associated with Low Risk of Venous Thromboembolism in Patients with Cancer: A Prospective and Observational Cohort Study. <i>Thrombosis Research</i> , 2014, 134, 1008-1013.	1.7	27
319	Testicular Cancer and Platinum: A Double-Edged Sword. <i>Journal of Clinical Oncology</i> , 2014, 32, e46-e48.	1.6	8
320	Predictive value of HDL cholesterol for cancer-associated venous thromboembolism during chemotherapy. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2049-2053.	3.8	8
321	Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 241-249.	2.1	26
322	Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1928-1931.	3.8	55
325	Effect of port-care frequency on venous port catheter-related complications in cancer patients. <i>International Journal of Clinical Oncology</i> , 2014, 19, 761-766.	2.2	18
326	Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model. <i>Clinical and Translational Oncology</i> , 2014, 16, 927-930.	2.4	46
327	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2014, 35, 3033-3080.	2.2	2,591
328	Platelets and Cancer-Associated Thrombosis. <i>Seminars in Oncology</i> , 2014, 41, 302-310.	2.2	48
330	Lack of Evidence to Support Thromboprophylaxis in Hospitalized Medical Patients with Cancer. <i>American Journal of Medicine</i> , 2014, 127, 82-86.e1.	1.5	132
331	Therapy for Cancer-Related Thromboembolism. <i>Seminars in Oncology</i> , 2014, 41, 319-338.	2.2	26
332	Primary prevention of cancer-related thrombosis: Special focus on ambulatory patients. <i>International Journal of Cardiology</i> , 2014, 173, 583-584.	1.7	18
334	Risk stratification strategies for cancer-associated thrombosis: an update. <i>Thrombosis Research</i> , 2014, 133, S35-S38.	1.7	93
335	Unconventional approaches to the prevention of cancer associated thrombosis. <i>Thrombosis Research</i> , 2014, 133, S44-S48.	1.7	5
336	Effect of resection of localized pancreaticobiliary adenocarcinoma on angiogenic markers and tissue factor related pro-thrombotic and pro-angiogenic activity. <i>Thrombosis Research</i> , 2014, 134, 479-487.	1.7	6
337	Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). <i>Thrombosis Research</i> , 2014, 133, S39-S43.	1.7	63
338	Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. <i>Thrombosis Research</i> , 2014, 133, S122-S127.	1.7	44
339	New strategies of VTE prevention in cancer patients. <i>Thrombosis Research</i> , 2014, 133, S128-S132.	1.7	9

#	ARTICLE	IF	CITATIONS
340	Predicting recurrent venous thromboembolism in cancer: is it possible?. Thrombosis Research, 2014, 133, S17-S22.	1.7	18
341	Heparins and cancer survival: where do we stand?. Thrombosis Research, 2014, 133, S133-S138.	1.7	31
342	Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. Thrombosis Research, 2014, 133, 25-29.	1.7	42
345	Thromboprophylaxis for medical patients with cancer: what do the guidelines say?. Clinical Practice (London, England), 2014, 11, 155-168.	0.1	1
349	Cancer Tissue Procoagulant Mechanisms and the Hypercoagulable State of Patients with Cancer. Seminars in Thrombosis and Hemostasis, 2015, 41, 756-764.	2.7	84
350	Guideline on aspects of cancer-related venous thrombosis. British Journal of Haematology, 2015, 170, 640-648.	2.5	139
351	Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. Journal of Thrombosis and Haemostasis, 2015, 13, 998-1003.	3.8	61
352	Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1079-1095.	4.9	100
353	Implications of cytogenetics for venous thromboembolism in acute myeloid leukaemia. Thrombosis and Haemostasis, 2015, 113, 201-208.	3.4	14
354	A health systems approach to risk stratification. Thrombosis Research, 2015, 136, 1049-1050.	1.7	0
355	Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data. Clinical Sarcoma Research, 2015, 5, 18.	2.3	8
356	Venous thrombosis in patients with high-grade glioma. Current Opinion in Oncology, 2015, 27, 516-521.	2.4	14
357	Venous thrombosis and cancer: from mouse models to clinical trials. Journal of Thrombosis and Haemostasis, 2015, 13, 1372-1382.	3.8	112
358	Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. Journal of Thrombosis and Haemostasis, 2015, 13, 1310-1319.	3.8	121
359	Pathogenesis and Diagnosis of Venous Hypercoagulable States in Cancer. Journal of Hematology & Thromboembolic Diseases, 2015, 03, .	0.1	1
361	Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies. PLoS Medicine, 2015, 12, e1001899.	8.4	35
362	Thrombosis in Lymphoma Patients and in Myeloma Patients. Keio Journal of Medicine, 2015, 64, 37-43.	1.1	17
363	Multimodality Imaging in Cardiooncology. Journal of Oncology, 2015, 2015, 1-9.	1.3	23

#	ARTICLE	IF	CITATIONS
364	Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. <i>Advances in Hematology</i> , 2015, 2015, 1-19.	1.0	11
365	Occurrence of Deep Vein Thrombosis among Hospitalized Non-Surgical Japanese Patients. <i>Annals of Vascular Diseases</i> , 2015, 8, 203-209.	0.5	15
366	Tromboembolismo Pulmonar no Doente Oncol�gico em Ambulat�rio. <i>Acta Medica Portuguesa</i> , 2015, 28, 463.	0.4	6
367	Efficacy of Prophylactic Low�Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2028-2034.	1.6	217
368	Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in ambulatory cancer patients at intermediate-high risk for venous thrombosis. <i>Thrombosis Research</i> , 2015, 136, 1099-1102.	1.7	41
369	Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio. <i>International Journal of Cancer</i> , 2015, 136, 1234-1240.	5.1	60
370	Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. <i>Thrombosis Research</i> , 2015, 135, 298-302.	1.7	49
371	The mechanisms of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2015, 135, S8-S11.	1.7	114
372	Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 399-406.	1.6	46
373	No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. <i>Thrombosis Research</i> , 2015, 135, 292-297.	1.7	23
375	Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With Chemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 582-587.	1.6	50
376	Management of cancer�associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 671-675.	3.8	55
377	Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 245-249.	2.1	25
378	Readmission rates due to venous thromboembolism in cancer patients after abdominopelvic surgery, a retrospective chart review. <i>Supportive Care in Cancer</i> , 2015, 23, 993-999.	2.2	8
379	Canadian Consensus Recommendations on the Management of Venous Thromboembolism in Patients with Cancer. Part 1: Prophylaxis. <i>Current Oncology</i> , 2015, 22, 133-143.	2.2	53
380	Epidemiology of venous thromboembolism. <i>Nature Reviews Cardiology</i> , 2015, 12, 464-474.	13.7	783
381	Application of ROTEM to assess hypercoagulability in patients with lung cancer. <i>Thrombosis Research</i> , 2015, 135, 1075-1080.	1.7	45
382	Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy. <i>Thrombosis Research</i> , 2015, 136, 673-681.	1.7	7

#	ARTICLE	IF	CITATIONS
383	The effect of adjuvant chemotherapy on plasma TAT and F 1+2 levels in patients with breast cancer. Biomedicine and Pharmacotherapy, 2015, 73, 19-23.	5.6	4
384	Evaluation of the Oncologic Patient Before, During, and After Chemotherapy. , 2015, , 157-186.		0
385	Safety of anticoagulant treatment in cancer patients. Expert Opinion on Drug Safety, 2015, 14, 1227-1236.	2.4	8
386	When to Offer Thromboprophylaxis to Patients With Advanced Pancreatic Cancer: Shedding Light on the Path Forward. Journal of Clinical Oncology, 2015, 33, 1995-1997.	1.6	7
387	A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients withÂcatheter-related thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 243-250.e1.	1.6	28
388	Novel or Nonâ€“Vitamin K Antagonist Oral Anticoagulants and the Treatment of Cancer-Associated Thrombosis. Seminars in Thrombosis and Hemostasis, 2015, 41, 237-243.	2.7	7
389	Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castrationâ€“resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer, 2015, 121, 1025-1031.	4.1	32
390	Predicting early mortality in resectable pancreatic adenocarcinoma: A cohort study. Cancer, 2015, 121, 1779-1784.	4.1	28
391	Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. Current Oncology, 2015, 22, 144.	2.2	47
392	Approach to chemotherapy-associated thrombosis. Vascular Medicine, 2015, 20, 153-161.	1.5	54
393	Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer â€“ a clinical prospective study of outcome and prognostic factors. Thrombosis Research, 2015, 135, 802-808.	1.7	27
398	Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung Cancer, 2015, 88, 80-84.	2.0	22
400	Thrombosis in Leukemia: Incidence, Causes, and Practical Management. Current Oncology Reports, 2015, 17, 444.	4.0	15
401	Thrombocytosis of Liver Metastasis from Colorectal Cancer as Predictive Factor. Pathology and Oncology Research, 2015, 21, 991-997.	1.9	12
402	Life-Threatening Complications and Outcomes in Patients with Malignancies and Severe Pulmonary Embolism. Thrombosis Research, 2015, 135, 610-615.	1.7	5
403	Venous thromboembolism (VTE) and glioblastoma. Journal of Neuro-Oncology, 2015, 124, 87-94.	2.9	68
404	Management of chemotherapy-induced thromboembolism in breast cancer. Breast Cancer Management, 2015, 4, 187-198.	0.2	0
405	Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic) Tj ETQq1 1 0,784314 rgBT /Overld	1.7	10

#	ARTICLE	IF	CITATIONS
406	Venous thromboembolism in cancer patients: an underestimated major health problem. <i>World Journal of Surgical Oncology</i> , 2015, 13, 204.	1.9	91
407	Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study. <i>Thrombosis Research</i> , 2015, 136, 1145-1148.	1.7	9
408	Pre-operative thrombotic complications of neoadjuvant chemotherapy for breast cancer: Implications for immediate breast reconstruction. <i>Annals of Medicine and Surgery</i> , 2015, 4, 80-84.	1.1	5
409	Central venous access in oncology: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2015, 26, v152-v168.	1.2	117
410	Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2015, 136, 1120-1125.	1.7	16
411	Venous thromboembolism and lung cancer: a review. <i>Multidisciplinary Respiratory Medicine</i> , 2015, 10, 28.	1.5	56
412	Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3105-3115.	1.6	107
414	Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS). <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 17-22.	3.8	61
415	The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 308, C229-C236.	4.6	29
416	Do we need antiplatelet therapy in thrombocytosis? <i>Pro. Hamostaseologie</i> , 2016, 36, 227-240.	1.9	7
417	Matching genes with constitution and environment. <i>Thrombosis and Haemostasis</i> , 2016, 116, 592-594.	3.4	0
418	Optimal management of venous thromboembolism in adolescent and young adult oncology patients. <i>Clinical Oncology in Adolescents and Young Adults</i> , 2016, Volume 6, 39-49.	0.8	2
419	Routine Hemostasis and Hemogram Parameters. <i>Chinese Medical Journal</i> , 2016, 129, 1772-1777.	2.3	5
420	Ronda clínica y epidemiológica: club de revistas. <i>Iatreia</i> , 2016, 29, .	0.1	0
421	Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies. <i>Healthcare (Switzerland)</i> , 2016, 4, 16.	2.0	8
422	Retrievable Inferior Vena Cava Filters in Patients with Cancer: Complications and Retrieval Success Rate. <i>International Journal of Vascular Medicine</i> , 2016, 2016, 1-8.	1.0	2
423	VEGF gene promoter polymorphisms and risk of VTE in chemotherapy-treated cancer patients. <i>Thrombosis and Haemostasis</i> , 2016, 115, 143-151.	3.4	13
424	Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants. <i>Frontiers in Cardiovascular Medicine</i> , 2016, 3, 24.	2.4	22

#	ARTICLE	IF	CITATIONS
425	Clinical practice guidelines for prophylaxis of venous thromboembolism in cancer patients. <i>Thrombosis and Haemostasis</i> , 2016, 116, 618-625.	3.4	18
428	Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnic. <i>Medicine (United States)</i> , 2016, 95, e3472.	1.0	24
429	Epidemiology and risk factors for venous thromboembolism in lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 145-149.	2.4	22
430	The Impact of Cancer on the Clinical Outcome of Patients After Inferior Vena Cava Filter Placement. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 294-301.	1.3	6
431	Safety of anticoagulation in the treatment of venous thromboembolism in patients with haematological malignancies and thrombocytopenia: Report of 5 cases and literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 92-99.	4.4	15
432	Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1773-1778.	3.8	113
433	Perioperative Respiratory Adverse Events in Pediatric Ambulatory Anesthesia: Development and Validation of a Risk Prediction Tool. <i>Anesthesia and Analgesia</i> , 2016, 122, 1578-1585.	2.2	53
434	Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 294-305.	3.8	52
435	Reply to M.G. McNamara et al and T.H. Oo. <i>Journal of Clinical Oncology</i> , 2016, 34, 516-517.	1.6	5
436	Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer. <i>Women's Health Issues</i> , 2016, 26, 574-583.	2.0	2
437	Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data. <i>British Journal of Cancer</i> , 2016, 115, 115-121.	6.4	56
438	ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 306-315.	3.8	60
439	Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. <i>The Cochrane Library</i> , 2016, 12, CD008500.	2.8	70
441	The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 326-330.	2.0	15
442	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016, 6, e010569.	1.9	18
443	Yield of computed tomography pulmonary angiogram in the emergency department in cancer patients suspected to have pulmonary embolism. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 131-136.	0.9	1
444	Thrombosis in the setting of cancer. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 196-205.	2.5	37
445	Cerebral ischemic events in patients with pancreatic cancer. <i>Medicine (United States)</i> , 2016, 95, e4009.	1.0	11

#	ARTICLE	IF	CITATIONS
446	Maladie veineuse thromboembolique et cancer. Revue Des Maladies Respiratoires Actualites, 2016, 8, 489-496.	0.0	0
447	Protocolo de profilaxis de la enfermedad tromboembólica venosa en procesos médicos y quirúrgicos. Medicine, 2016, 12, 1309-1314.	0.0	0
448	A review of the venous thrombotic issues associated with multiple myeloma. Expert Review of Hematology, 2016, 9, 695-706.	2.2	21
449	Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients. Oncologist, 2016, 21, 252-257.	3.7	63
450	Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thrombosis Research, 2016, 143, 86-90.	1.7	37
451	Insulin resistance as a predictor of venous thromboembolism in breast cancer. Endocrine-Related Cancer, 2016, 23, L25-L28.	3.1	9
452	Prophylaxis of venous thromboembolism in cancer patients. Expert Review of Hematology, 2016, 9, 535-539.	2.2	7
453	Venous thromboembolism in cancer patients: risk assessment, prevention and management. Future Cardiology, 2016, 12, 221-235.	1.2	2
454	Cancer-associated thrombosis. Disease-a-Month, 2016, 62, 121-158.	1.1	55
455	Predictors of Venous Thromboembolism in Patients with Glioblastoma. Pathology and Oncology Research, 2016, 22, 311-316.	1.9	10
456	Cancer associated thrombosis: risk factors and outcomes. Thrombosis Research, 2016, 140, S12-S17.	1.7	64
457	Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. Thrombosis Research, 2016, 140, S93-S98.	1.7	26
458	Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer. Thrombosis Research, 2016, 141, 39-48.	1.7	31
459	Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis. Annals of Hematology, 2016, 95, 1457-1464.	1.8	48
460	Erythrocyte-related phenotypes and genetic susceptibility to thrombosis. Blood Cells, Molecules, and Diseases, 2016, 59, 44-48.	1.4	2
461	Handbook of Thromboprophylaxis. , 2016, , .		0
462	The Role of Inferior Vena Cava Filters in Cancer Patients. Seminars in Interventional Radiology, 2016, 33, 071-074.	0.8	15
463	Primary prophylaxis of VTE in cancer outpatients. Thrombosis Research, 2016, 140, S103-S108.	1.7	6

#	ARTICLE	IF	CITATIONS
464	When are breast cancer patients at highest risk of venous thromboembolism? A cohort study using English health care data. <i>Blood</i> , 2016, 127, 849-857.	1.4	93
465	Breast cancer and thrombosis: timing matters. <i>Blood</i> , 2016, 127, 793-794.	1.4	7
466	Shooting the messenger (RNA) in B-cell lymphoma. <i>Blood</i> , 2016, 127, 794-796.	1.4	1
467	Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism. <i>Haematologica</i> , 2016, 101, 1046-1053.	3.5	28
468	Prevention of Venous Thromboembolism. , 2016, , 429-443.		0
469	Comparison of postoperative venous thromboembolism incidence in gastrointestinal and gynecologic solid tumors. <i>Thrombosis Research</i> , 2016, 147, 104-107.	1.7	3
470	Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population. <i>Breast</i> , 2016, 30, 13-18.	2.2	9
471	Practice Patterns for Prophylaxis and Treatment of Venous Thromboembolism in German Cancer Patients. <i>Oncology Research and Treatment</i> , 2016, 39, 194-201.	1.2	17
473	A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Pharmacological Reports</i> , 2016, 68, 1140-1148.	3.3	13
474	International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2016, 17, e452-e466.	10.7	315
475	Risk of venous thromboembolism in hospitalised cancer patients in England—a cohort study. <i>Journal of Hematology and Oncology</i> , 2016, 9, 60.	17.0	18
476	Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?. <i>Thrombosis Research</i> , 2016, 145, 51-53.	1.7	122
477	Update on the Management of Pancreatic Cancer in Older Adults. <i>Current Oncology Reports</i> , 2016, 18, 60.	4.0	8
478	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 309-325.	329.8	485
479	The use of novel oral anticoagulants in cancer patients with venous thromboembolism. <i>Seminars in Oncology</i> , 2016, 43, 655-665.	2.2	3
480	Hypercoagulation and complement: Connected players in tumor development and metastases. <i>Seminars in Immunology</i> , 2016, 28, 578-586.	5.6	49
482	Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. <i>American Journal of Hematology</i> , 2016, 91, 1014-1019.	4.1	55
483	High Rates of Thromboembolic Events in Patients with Germ Cell Cancer Undergoing Cisplatin-Based Polychemotherapy. <i>Urologia Internationalis</i> , 2016, 96, 399-405.	1.3	20

#	ARTICLE	IF	CITATIONS
484	Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. <i>European Journal of Cancer</i> , 2016, 69, 151-157.	2.8	31
485	Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. <i>Journal of Surgical Oncology</i> , 2016, 114, 581-586.	1.7	23
486	A systematic review of biomarkers for the prediction of thromboembolism in lung cancer â€” Results, practical issues and proposed strategies for future risk prediction models. <i>Thrombosis Research</i> , 2016, 148, 63-69.	1.7	19
487	Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5249-5255.	7.0	12
489	Retrospective analysis of cardiovascular diseases related to chemotherapies for advanced solid tumor patients. <i>Anti-Cancer Drugs</i> , 2016, 27, 891-898.	1.4	3
490	The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. <i>Cancer</i> , 2016, 122, 712-721.	4.1	25
491	Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy. <i>Blood Coagulation and Fibrinolysis</i> , 2016, 27, 270-274.	1.0	32
492	Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. <i>Cancer Research</i> , 2016, 76, 3671-3675.	0.9	27
494	Venous thromboembolism after surgical treatment of non-spinal skeletal metastases â€” An underdiagnosed complication. <i>Thrombosis Research</i> , 2016, 141, 124-128.	1.7	12
495	Breast cancer-associated venous thromboembolism: A caseâ€”control study. <i>Breast</i> , 2016, 28, 84-88.	2.2	6
496	The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence â€” 15 Years and Counting. <i>Thrombosis Research</i> , 2016, 140, S99-S102.	1.7	0
497	Thromboprophylaxis in Cancer Patients. , 2016, , 97-109.		0
498	A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. <i>Oncologist</i> , 2016, 21, 861-867.	3.7	54
499	Incidence and Risk Factors Related to Symptomatic Venous Thromboembolic Events After Esophagectomy for Cancer. <i>Annals of Thoracic Surgery</i> , 2016, 102, 979-984.	1.3	22
500	Reply to M.G. McNamara et al and T.H. Oo. <i>Journal of Clinical Oncology</i> , 2016, 34, 517-518.	1.6	0
501	Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy. <i>European Journal of Cancer</i> , 2016, 63, 180-188.	2.8	25
502	Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 839-848.	2.4	17
504	The epidemiology of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 3-14.	2.1	749

#	ARTICLE	IF	CITATIONS
505	Guidance for the prevention and treatment of cancer-associated venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2016, 41, 81-91.	2.1	169
506	Risk factors for incident venous thromboembolism in active cancer patients: A population based caseâ€“control study. Thrombosis Research, 2016, 139, 29-37.	1.7	58
507	Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Thrombosis Research, 2016, 139, 65-76.	1.7	162
508	Thromboembolic Events in Malignant Pleural Mesothelioma. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 390-394.	1.7	6
509	The Role of Platelets in Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2016, 42, 242-251.	2.7	56
510	â€œIf You Prick Us, Do We Not Bleed?â€•Whom Should We Choose?. Journal of Clinical Oncology, 2016, 34, 513-514.	1.6	3
511	Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer. Chest, 2016, 149, 1245-1251.	0.8	38
512	Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. Journal of Clinical Oncology, 2016, 34, 488-494.	1.6	138
513	Venous Thromboembolism in Patients Diagnosed With Lung Cancer. Angiology, 2016, 67, 709-724.	1.8	26
514	Trousseau's syndrome: cancer-associated thrombosis. Japanese Journal of Clinical Oncology, 2016, 46, 204-208.	1.3	133
515	Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS). Clinical Cancer Research, 2016, 22, 200-206.	7.0	39
516	Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients. Supportive Care in Cancer, 2016, 24, 1199-1208.	2.2	11
517	Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer. Journal of Urology, 2016, 195, 33-40.	0.4	23
518	The prothrombotic activity of cancer cells in the circulation. Blood Reviews, 2016, 30, 11-19.	5.7	77
519	Biomarkers for Prediction of Central Venous Catheter Related-Thrombosis in Patients With Hematological Malignancies. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 779-784.	1.7	7
520	Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome. Leukemia, 2017, 31, 100-106.	7.2	57
521	Safety and efficacy of primary thromboprophylaxis in cancer patients. Clinical and Translational Oncology, 2017, 19, 1-11.	2.4	16
522	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Medicine, 2017, 6, 186-194.	2.8	12

#	ARTICLE	IF	CITATIONS
523	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95.	1.7	109
524	Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool. <i>American Journal of Hematology</i> , 2017, 92, 501-507.	4.1	60
525	Management of Cancer-Associated Venous Thromboembolism in the Emergency Department. <i>Annals of Emergency Medicine</i> , 2017, 69, 768-776.	0.6	2
526	Cancer and Venous Thromboembolic Disease: A Review. <i>Oncologist</i> , 2017, 22, 199-207.	3.7	160
527	Risk Assessment Scores for Cancer-Associated Venous Thromboembolic Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 469-478.	2.7	22
528	Cardio-Oncology. , 2017, , .		1
529	Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. <i>Thrombosis Research</i> , 2017, 154, 28-34.	1.7	36
530	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017, 22, 601-608.	3.7	108
531	The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the <scp>SAVE</scp>â€œ<scp>ONCO</scp> trial control arm. <i>American Journal of Hematology</i> , 2017, 92, E101-E103.	4.1	7
532	Vascular Complications of Cancer and Cancer Therapy. , 2017, , 215-240.		0
533	High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. <i>Pancreatology</i> , 2017, 17, 629-634.	1.1	16
535	Supportive care in pancreatic ductal adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 1293-1302.	2.4	26
536	Prophylaxis for Venous Thromboembolism. <i>Critical Care Nursing Quarterly</i> , 2017, 40, 219-229.	0.8	1
537	Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw265.	6.3	9
538	Retrospective Evaluation of Thromboembolism Risk in Ovarian Cancer Patients Treated with Bevacizumab. <i>Targeted Oncology</i> , 2017, 12, 495-503.	3.6	14
539	Venous Thromboembolism. <i>Obstetrics and Gynecology</i> , 2017, 129, 971-973.	2.4	1
540	A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASSâ€œCancer-Associated Thrombosis Study. <i>Oncologist</i> , 2017, 22, 1222-1231.	3.7	167
541	Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. <i>Haematologica</i> , 2017, 102, 1494-1501.	3.5	164

#	ARTICLE	IF	CITATIONS
542	Oral Anticoagulation Therapy. , 2017, , .		1
543	Reply by Authors. Journal of Urology, 2017, 197, 1361-1362.	0.4	0
544	Circulating tumor cells and coagulationâ€”Minireview. Critical Reviews in Oncology/Hematology, 2017, 114, 33-42.	4.4	14
545	The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thrombosis Research, 2017, 150, 30-32.	1.7	70
546	Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: comment. Journal of Thrombosis and Haemostasis, 2017, 15, 590-591.	3.8	23
547	Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clinical and Translational Oncology, 2017, 19, 667-681.	2.4	27
548	Advances in managing and preventing thromboembolic disease in cancer patients. Current Opinion in Supportive and Palliative Care, 2017, 11, 347-354.	1.3	5
549	A Test in Context: D-Dimer. Journal of the American College of Cardiology, 2017, 70, 2411-2420.	2.8	342
550	Prevention and treatment of cancer-associated thrombosis in France: A national survey among vascular disease and supportive care specialists. JMV-Journal De Medecine Vasculaire, 2017, 42, 255-262.	0.2	5
551	Incidence, risk factors, and outcomes of central venous catheterâ€”related thromboembolism in breast cancer patients: the <scp>CAVECCAS</scp> study. Cancer Medicine, 2017, 6, 2732-2744.	2.8	30
552	Risk factors of occult malignancy in patients with unprovoked venous thromboembolism. Thrombosis Research, 2017, 159, 48-51.	1.7	15
553	Clinical and laboratory assessment of a patient with thrombocytosis. British Journal of Hospital Medicine (London, England: 2005), 2017, 78, 558-564.	0.5	7
554	Identification of target gene of venous thromboembolism in patients with lymphoma via microarray analysis. Oncology Letters, 2017, 14, 3313-3318.	1.8	1
555	Manual of Cardio-oncology. , 2017, , .		1
556	Thromboembolic Disorders as a Consequence of Cancer. , 2017, , 57-74.		0
557	Mechanisms and risk factors of thrombosis in cancer. Critical Reviews in Oncology/Hematology, 2017, 118, 79-83.	4.4	183
558	Cancer-associated pathways and biomarkers of venous thrombosis. Blood, 2017, 130, 1499-1506.	1.4	277
559	Coagulation and fibrinolysis in gastric cancer. Annals of the New York Academy of Sciences, 2017, 1404, 27-48.	3.8	87

#	ARTICLE	IF	CITATIONS
560	Predictive Factors for Developing Venous Thrombosis during Cisplatin-Based Chemotherapy in Testicular Cancer. <i>Urologia Internationalis</i> , 2017, 99, 104-109.	1.3	21
561	Venous thromboembolism prophylaxis for ambulatory cancer patients, can we do better?. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 399-405.	2.1	8
562	Circulating tumor cell count and thrombosis in metastatic breast cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1981-1988.	3.8	11
563	Risk of Arterial Thromboembolism in Patients With Cancer. <i>Journal of the American College of Cardiology</i> , 2017, 70, 926-938.	2.8	465
564	Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study. <i>Thrombosis Research</i> , 2017, 158, 49-58.	1.7	17
565	Venous thromboembolism risk and prophylaxis in the Portuguese hospital care setting: The ARTE study. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 823-830.	0.5	8
566	Cardiovascular Complications of Cancer Therapy. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2552-2565.	2.8	221
567	Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer. <i>Convergent Science Physical Oncology</i> , 2017, 3, 023001.	2.6	38
568	Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study. <i>BMC Cancer</i> , 2017, 17, 351.	2.6	15
569	Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study. <i>BMC Cancer</i> , 2017, 17, 415.	2.6	13
570	Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer – A retrospective cohort study. <i>Thrombosis Research</i> , 2017, 157, 9-15.	1.7	49
571	Incidence and risk factors for preoperative deep venous thrombosis in 314 consecutive patients undergoing surgery for spinal metastasis. <i>Journal of Neurosurgery: Spine</i> , 2017, 27, 189-197.	1.7	33
572	Thrombelastography coagulation index may be a predictor of venous thromboembolism in gynecological oncology patients. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 202-210.	1.3	16
573	Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 456-464.	1.7	19
574	Risk Assessment for Venous Thromboembolism in Chemotherapy-Treated Ambulatory Cancer Patients. <i>Medical Decision Making</i> , 2017, 37, 234-242.	2.4	63
575	The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 755-760.	1.7	17
576	Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study. <i>Cancer</i> , 2017, 123, 468-475.	4.1	31
577	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	3.4	53

#	ARTICLE	IF	CITATIONS
579	Apixaban and dalteparin in active malignancy associated venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1952-1961.	3.4	62
580	Venous thromboembolism in Portuguese hospitals: Where we stand and how we can improve. <i>Revista Portuguesa De Cardiologia</i> , 2017, 36, 831-832.	0.5	1
581	Venous thromboembolism in Portuguese hospitals: Where we stand and how we can improve. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 831-832.	0.2	0
582	Venous thromboembolism risk and prophylaxis in the Portuguese hospital care setting: The ARTE study. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2017, 36, 823-830.	0.2	5
583	Cancer-associated venous thromboembolism: Burden, mechanisms, and management. <i>Thrombosis and Haemostasis</i> , 2017, 117, 219-230.	3.4	337
584	Predictors of active cancer thromboembolic outcomes. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1192-1198.	3.4	20
585	Cumulative incidence, risk factors and prognostic impact of venous thromboembolism in Japanese patients with advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 942-948.	1.3	7
586	Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1615-1621.	3.4	27
587	Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 136-143.	2.5	4
588	Multiple recurrent ischaemic strokes in a patient with cancer: is there a role for the initiation of anticoagulation therapy for secondary stroke prevention?. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2016-218105.	0.5	4
589	“Systemic Strategy at the Patient's Service” A Congress Report on Supportive Care in Oncology. <i>Tumori</i> , 2017, 103, P1-P8.	1.1	0
590	Cancer and Thrombotic Risk: The Platelet Paradigm. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 67.	2.4	18
591	Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology. <i>Disease Markers</i> , 2017, 2017, 1-7.	1.3	49
592	Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. <i>PLoS ONE</i> , 2017, 12, e0176283.	2.5	39
593	Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study. <i>JNCI Cancer Spectrum</i> , 2017, 1, pkx009.	2.9	6
594	Genotype-driven identification of a molecular network predictive of advanced coronary calcium in ClinSeq [®] and Framingham Heart Study cohorts. <i>BMC Systems Biology</i> , 2017, 11, 99.	3.0	20
595	Predictors of active cancer thromboembolic outcomes: mortality associated with calf deep vein thrombosis. <i>International Angiology</i> , 2017, 36, 553-557.	0.9	10
596	Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 363.	2.0	13

#	ARTICLE	IF	CITATIONS
597	Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1078-1085.	1.6	60
598	Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?. <i>Journal of Global Oncology</i> , 2017, 3, 15-22.	0.5	12
599	Tissue Factor: Catch Me If You Can!. <i>Journal of Clinical Oncology</i> , 2017, 35, 1128-1130.	1.6	11
600	Thrombosis in cancer patients: etiology, incidence, and management. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S178-S185.	1.7	52
601	Predictors of active cancer thromboembolic outcomes: role of body composition. <i>International Angiology</i> , 2017, 36, 88-89.	0.9	1
602	Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2018, 17, 121-128.	2.3	21
603	Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 41-50.	4.4	26
604	Anticoagulation in the Patient with Cancer. , 2018, , 425-440.		1
605	Current and future burden of venous thrombosis: Not simply predictable. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 199-208.	2.3	52
606	Impact of time since diagnosis and mortality rate on cancer-associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1327-1335.	3.8	18
607	Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial. <i>Thrombosis Research</i> , 2018, 164, S124-S129.	1.7	28
608	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , 2018, 131, 972.e1-972.e7.	1.5	29
609	Effect of rosuvastatin on risk markers for venous thromboembolism in cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1099-1106.	3.8	6
610	Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients. <i>Medical Oncology</i> , 2018, 35, 63.	2.5	39
611	Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016. <i>Cancer Investigation</i> , 2018, 36, 73-91.	1.3	1
612	Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future. <i>Thrombosis Research</i> , 2018, 164, S70-S76.	1.7	53
613	The role of extended venous thromboembolism prophylaxis following urologic pelvic surgery. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 83-87.	1.6	6
614	Venous Thromboembolism Risk in Head and Neck Cancer: Significance of the Preoperative Platelet-to-Lymphocyte Ratio. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 159, 85-91.	1.9	16

#	ARTICLE	IF	CITATIONS
615	Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review. <i>Thrombosis Research</i> , 2018, 163, 138-145.	1.7	20
616	Genes associated with venous thromboembolism in colorectal cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 293-302.	3.8	26
617	Predictive factors of thromboembolic complications in patients with esophagogastric adenocarcinoma undergoing preoperative chemotherapy. <i>Acta Oncológica</i> , 2018, 57, 790-798.	1.8	12
618	Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 508-518.	3.8	202
619	Arterial Thromboembolism in Non-Hodgkin Lymphoma. <i>Journal of the American College of Cardiology</i> , 2018, 71, 258-259.	2.8	0
620	Mouse models of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2018, 164, S48-S53.	1.7	34
621	Managing thrombosis in cancer patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 429-438.	2.3	40
622	Cancer prognosis in patients with venous thromboembolism (VTE) and patients with clinical and laboratory biomarkers predictive of VTE risk. <i>Thrombosis Research</i> , 2018, 164, S19-S22.	1.7	6
623	Predictors of Early Mortality in Cancer-Associated Thrombosis: Analysis of the RIETE Database. <i>TH Open</i> , 2018, 02, e158-e166.	1.4	5
624	Consensus statement for cancer patients requiring intensive care support. <i>Annals of Hematology</i> , 2018, 97, 1271-1282.	1.8	69
625	Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos. <i>Archivos De Bronconeumología</i> , 2018, 54, 359-360.	0.8	1
626	Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced <i>ALK</i>-rearranged non-small cell lung cancer. <i>European Respiratory Journal</i> , 2018, 51, 1702431.	6.7	32
627	Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. <i>British Journal of Cancer</i> , 2018, 118, 1056-1061.	6.4	89
628	Novel Mechanism of Cancer Thrombosis Induced by Microvesicles. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 692-694.	2.4	1
629	Preoperative Incidence of Deep Venous Thrombosis in Patients With Bladder Cancer Undergoing Radical Cystectomy. <i>Urology</i> , 2018, 116, 120-124.	1.0	15
630	Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies. <i>Thrombosis and Haemostasis</i> , 2018, 118, S23-S33.	3.4	12
631	Developing and validating a center-specific preoperative prediction calculator for risk of pancreaticoduodenectomy. <i>American Journal of Surgery</i> , 2018, 216, 498-505.	1.8	5
632	The Application of Current Proposed Venous Thromboembolism Risk Assessment Model for Ambulatory Patients With Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 429-433.	1.7	17

#	ARTICLE	IF	CITATIONS
633	Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 471-476.	1.7	29
634	Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. <i>European Heart Journal</i> , 2018, 39, 4208-4218.	2.2	267
635	Association between Level of Tumor Markers and Development of VTE in Patients with Pancreatic, Colorectal and Ovarian Ca: Retrospective Case- Control Study in Two Community Hospitals. <i>Pathology and Oncology Research</i> , 2018, 24, 283-287.	1.9	11
636	Key points to optimizing management and research on cancer-associated thrombosis. <i>Clinical and Translational Oncology</i> , 2018, 20, 119-126.	2.4	2
637	Venous thromboembolic events in lymphoma patients: Actual relationships between epidemiology, mechanisms, clinical profile and treatment. <i>Blood Reviews</i> , 2018, 32, 144-158.	5.7	15
638	Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and meta-analysis of randomized controlled trials (RCTs). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 210-216.	1.1	20
639	Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). <i>Oncologist</i> , 2018, 23, 247-255.	3.7	63
640	Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e113-e120.	1.9	7
641	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e161-e167.	1.9	3
642	Performance of Current Thromboembolism Risk Assessment Tools in Patients With Gastric Cancer and Validity After First Treatment. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 790-796.	1.7	14
643	Neurological Complications of Breast Cancer and Its Treatment. , 2018, , 435-469.		0
644	Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 77.e9-77.e13.	1.6	23
645	The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 175-180.	3.8	17
646	Supportive Care. , 2018, , 649-656.		0
647	Top ten errors of statistical analysis in observational studies for cancer research. <i>Clinical and Translational Oncology</i> , 2018, 20, 954-965.	2.4	17
648	Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score. <i>Medical Oncology</i> , 2018, 35, 5.	2.5	33
649	Presentation and Significance of Venous Thromboembolism. , 2018, , 245-263.		0
650	Clinical prediction rules for mortality in patients with pulmonary embolism and cancer to guide outpatient management: a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 279-292.	3.8	11

#	ARTICLE	IF	CITATIONS
651	Towards a precision medicine in venous thromboembolism associated to lung cancer. Journal of Thoracic Disease, 2018, 10, S3064-S3066.	1.4	1
652	Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study. BMC Cancer, 2018, 18, 1260.	2.6	19
653	High Risk of Venous Thromboembolism After Surgery for Long Bone Metastases: A Retrospective Study of 682 Patients. Clinical Orthopaedics and Related Research, 2018, 476, 2052-2061.	1.5	22
654	Venous Thromboembolism and Peri-Operative Chemotherapy for Muscle-Invasive Bladder Cancer: A Population-based Study. Bladder Cancer, 2018, 4, 419-428.	0.4	13
655	Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study. Oncologist, 2018, 23, 1372-1381.	3.7	36
656	Characterization of Risk Factors and Timing of Venous Thromboembolism in Patients With Uterine Serous Carcinoma. Obstetrics and Gynecology, 2018, 132, 1130-1136.	2.4	3
657	Incidence, Risk Factors, and Outcomes of Arterial Thromboembolism in Patients with Pancreatic Cancer Following Palliative Chemotherapy. Cancers, 2018, 10, 432.	3.7	4
658	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. Cancers, 2018, 10, 450.	3.7	51
659	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. Blood Cancer Journal, 2018, 8, 102.	6.2	23
660	Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines—A Multidisciplinary (SEMI—SEOM—SETH) Expert Consensus. TH Open, 2018, 02, e373-e386.	1.4	17
661	Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset. Cancers, 2018, 10, 501.	3.7	19
662	Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study. Ecancermedicalscience, 2018, 12, 876.	1.1	5
663	Testicular cancer. Nature Reviews Disease Primers, 2018, 4, 29.	30.5	299
664	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. Thrombosis and Haemostasis, 2018, 118, 1875-1884.	3.4	38
665	Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: Preliminary results from a risk score. Clinics, 2018, 73, e368.	1.5	12
666	Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers, 2018, 10, 380.	3.7	373
667	The prevalence and risk factors of venous thromboembolism in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. Clinical Respiratory Journal, 2018, 12, 2573-2580.	1.6	18
668	Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 781-787.	0.4	8

#	ARTICLE	IF	CITATIONS
669	Ability of the Khorana score to predict recurrent thromboembolism in cancer patients with ischemic stroke. <i>Journal of Clinical Neuroscience</i> , 2018, 57, 111-115.	1.5	3
670	The Society for Translational Medicine: the assessment and prevention of venous thromboembolism after lung cancer surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, 3039-3053.	1.4	18
671	Venous Thromboembolic Disease and Cancer: A Challenge for Clinicians. <i>Archivos De Bronconeumologia</i> , 2018, 54, 359-360.	0.8	0
672	Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis. <i>Thrombosis Research</i> , 2018, 167, 50-56.	1.7	5
673	Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. <i>Cancer Medicine</i> , 2018, 7, 2868-2875.	2.8	19
674	Cancer-related circulating and tumor-associated neutrophils "subtypes, sources and function. <i>FEBS Journal</i> , 2018, 285, 4316-4342.	4.7	156
675	Prevalence of venous thromboembolism diagnosed in emergency department visits by cancer patients and associated healthcare resource utilization in the United States. <i>American Journal of Hematology</i> , 2018, 93, E207.	4.1	1
676	Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies. <i>Blood Coagulation and Fibrinolysis</i> , 2018, 29, 227-230.	1.0	0
677	Bleeding and venous thromboembolic events in patients with active cancer hospitalized for an acute medical illness. <i>Thrombosis Research</i> , 2018, 169, 44-49.	1.7	8
678	Clinical Course and Complications of Catheter and Non-Catheter-Related Upper Extremity Deep Vein Thrombosis in Patients with Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1234-1240.	1.7	10
679	Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e20-e25.	2.0	9
680	Cancer-associated thrombosis: The search for the holy grail continues. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 622-629.	2.3	21
681	Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography. <i>Journal of Cardiovascular Imaging</i> , 2018, 26, 1.	0.8	24
682	The incidence and predictors of symptomatic venous thromboembolism associated with peripherally inserted central catheters in patients with nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3119-3127.	2.0	8
683	Risk assessment as a guide for the prevention of cancer-associated thromboembolism. <i>International Angiology</i> , 2018, 37, 269-276.	0.9	5
684	Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOICP). <i>Blood</i> , 2018, 132, 707-716.	1.4	47
685	Khorana Score: New Predictor of Early Mortality in Patients With Lung Adenocarcinoma. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1347-1351.	1.7	22
686	Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1336-1346.	3.8	23

#	ARTICLE	IF	CITATIONS
687	Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look!. Thrombosis Journal, 2018, 16, 2.	2.1	32
688	Incidence, predictive factors, management, and survival impact of atrial fibrillation in non-Hodgkin lymphoma. Annals of Hematology, 2018, 97, 1633-1640.	1.8	9
689	Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer. Journal of Thrombosis and Haemostasis, 2018, 16, 1321-1326.	3.8	34
690	The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis. Cancers, 2018, 10, 271.	3.7	33
691	Prevention of Deep Vein Thrombosis and Pulmonary Embolism in High-Risk Medical Patients. Clinics in Chest Medicine, 2018, 39, 483-492.	2.1	9
692	Real-world features associated with cancer-related venous thromboembolic events. ESMO Open, 2018, 3, e000363.	4.5	7
694	Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization. Blood Cancer Journal, 2018, 8, 54.	6.2	17
695	Thromboembolism Incidence and Risk Factors in Children with Cancer: A Population-Based Cohort Study. Thrombosis and Haemostasis, 2018, 118, 1646-1655.	3.4	15
696	The role of neutrophils in thrombosis. Thrombosis Research, 2018, 170, 87-96.	1.7	117
697	Venous Thromboembolism and Cancer. Current Cardiology Reports, 2018, 20, 89.	2.9	30
698	Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1267-1275.	1.7	11
699	A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematology,the, 2018, 5, e289-e298.	4.6	219
700	Simplicity versus complexity: an existential dilemma as risk tools evolve. Lancet Haematology,the, 2018, 5, e273-e274.	4.6	14
701	Venous Thromboembolism: Role of the Clinical Laboratory in Diagnosis and Management. journal of applied laboratory medicine, The, 2019, 3, 870-882.	1.3	20
702	Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer. Clinical and Translational Oncology, 2019, 21, 249-258.	2.4	4
703	Venous thromboembolism incidence in hematologic malignancies. Blood Reviews, 2019, 33, 24-32.	5.7	69
704	Direct Oral Anticoagulants in Cancer Patients. Seminars in Thrombosis and Hemostasis, 2019, 45, 638-647.	2.7	7
705	Venous thromboembolism in epithelial ovarian cancer. A prospective cohort study. Thrombosis Research, 2019, 181, 112-119.	1.7	15

#	ARTICLE	IF	CITATIONS
706	Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2141-2151.	3.8	41
707	Risks and Benefits of Anticoagulation in Cancer and Noncancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 629-637.	2.7	8
708	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2019, 94, 1176-1184.	4.1	112
709	Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2152-2159.	3.8	15
710	Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients. <i>Cancer Treatment and Research</i> , 2019, 179, 11-36.	0.5	56
711	Biomarkers of Cancer-Associated Thromboembolism. <i>Cancer Treatment and Research</i> , 2019, 179, 69-85.	0.5	7
712	The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1772-1778.	3.8	107
713	Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE Database. <i>International Angiology</i> , 2019, 38, 173-184.	0.9	17
714	Risk of Thrombosis in Cancer: Clinical Factors and Role of Primary Prophylaxis. <i>Cancer Treatment and Research</i> , 2019, 179, 55-68.	0.5	3
715	Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview. <i>Cancer Treatment and Research</i> , 2019, 179, 1-9.	0.5	9
716	Validation of the Khorana score in acute myeloid leukemia patients: a single-institution experience. <i>Thrombosis Journal</i> , 2019, 17, 13.	2.1	19
717	Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. <i>F1000Research</i> , 2019, 8, 974.	1.6	11
719	Anti-cancer drugs-induced arterial injury: risk stratification, prevention, and treatment. <i>Medical Oncology</i> , 2019, 36, 72.	2.5	4
720	Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies. <i>TH Open</i> , 2019, 03, e153-e156.	1.4	0
721	Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis. <i>Cells</i> , 2019, 8, 716.	4.1	39
722	Predicting outcomes in patients with cancer and atrial fibrillation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471986067.	2.1	7
723	<p>Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients</p>. <i>Vascular Health and Risk Management</i> , 2019, Volume 15, 175-186.	2.3	19
724	Update in thrombosis and hemostasis: ASH meeting 2018. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 212-215.	0.5	1

#	ARTICLE	IF	CITATIONS
725	Machine learning approaches for risk assessment of peripherally inserted Central catheter-related vein thrombosis in hospitalized patients with cancer. International Journal of Medical Informatics, 2019, 129, 175-183.	3.3	21
726	Direct oral anticoagulants in patients with cancer. American Journal of Health-System Pharmacy, 2019, 76, 1019-1027.	1.0	2
727	Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation. Cancer, 2019, 125, 4498-4508.	4.1	9
728	Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy. PLoS ONE, 2019, 14, e0224709.	2.5	4
729	Modeling Complexity: The Case of Cancer-Related Venous Thromboembolism. Thrombosis and Haemostasis, 2019, 119, 1713-1715.	3.4	1
730	Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy. Thrombosis Research, 2019, 183, 131-135.	1.7	12
731	Oncologic Emergencies: Too Much Clotting—Venous Thromboembolism in Malignancy. Journal of Emergency Medicine, 2019, 57, 825-835.	0.7	5
733	Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. Cancers, 2019, 11, 48.	3.7	16
734	Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer. Thrombosis and Haemostasis, 2019, 119, 1849-1859.	3.4	24
735	Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1100-1109.	1.8	1
736	Women, thrombosis, and cancer. Thrombosis Research, 2019, 181, S47-S53.	1.7	7
737	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	10.7	458
738	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Respiratory Journal, 2019, 54, 1901647.	6.7	806
739	Development and Validation of a Risk Scoring System for Cephamycin-Associated Hemorrhagic Events. Scientific Reports, 2019, 9, 12905.	3.3	3
740	Incidental pulmonary embolism in pancreatic ductal adenocarcinoma: Impact of tumor and AJCC stages at initial staging CT. Pancreatology, 2019, 19, 979-984.	1.1	0
741	<p><p>Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study</p></p>. Cancer Management and Research, 2019, Volume 11, 8379-8389.	1.9	13
742	Cerebral venous thrombosis as an initial manifestation of acute myeloid leukemia. Oxford Medical Case Reports, 2019, 2019, omy118.	0.4	2
743	Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers, 2019, 11, 95.	3.7	33

#	ARTICLE	IF	CITATIONS
744	Thrombin Generation and Cancer: Contributors and Consequences. <i>Cancers</i> , 2019, 11, 100.	3.7	65
745	Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer. <i>BJU International</i> , 2019, 124, 290-296.	2.5	3
746	Low incidence of thromboembolism in multiple myeloma patients receiving immunomodulatory drugs; a retrospective single-institution analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 141-148.	2.1	6
747	Factores predictores de trombosis en pacientes con c�ncer. <i>Archivos De Bronconeumologia</i> , 2019, 55, 67-68.	0.8	1
748	The risk of arterial thromboembolic events after cancer diagnosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 639-651.	2.3	13
749	Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961985643.	1.7	3
750	Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. <i>Annals of Oncology</i> , 2019, 30, 1329-1334.	1.2	23
751	Hodgkin lymphoma, treatment and thrombosis: a dangerous mix. <i>Annals of Oncology</i> , 2019, 30, 1192-1193.	1.2	1
752	Point-of-Care Ultrasound for Oncologic Critical Care. , 2019, , 1-18.		0
753	Tumour-associated neutrophils in patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 601-620.	27.6	558
754	Use of Viscoelastography in Malignancy-Associated Coagulopathy and Thrombosis: A Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 354-372.	2.7	32
755	Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 226-233.	2.3	14
756	Association of complete blood count parameters, d�dimer, and soluble P�selectin with risk of arterial thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1335-1344.	3.8	25
757	Comparison and screening of different risk assessment models for deep vein thrombosis in patients with solid tumors. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 292-298.	2.1	7
758	Thrombotic Complications in Gliomas. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 326-333.	2.7	10
759	The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 321-325.	2.7	67
760	Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961984656.	1.7	6
761	Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials. <i>Drugs</i> , 2019, 79, 621-631.	10.9	3

#	ARTICLE	IF	CITATIONS
762	Anticoagulation Strategies in Patients With Cancer. Journal of the American College of Cardiology, 2019, 73, 1336-1349.	2.8	121
763	Pancreatic cancer: Best supportive care. Presse Medicale, 2019, 48, e175-e185.	1.9	21
764	Cancer-associated thrombosis: the when, how and why. European Respiratory Review, 2019, 28, 180119.	7.1	160
765	Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations 2019 update. International Journal of Gynecological Cancer, 2019, 29, 651-668.	2.5	452
766	Updates on thrombotic events associated with multiple myeloma. Expert Review of Hematology, 2019, 12, 355-365.	2.2	11
767	Can Biomarkers of Coagulation, Platelet Activation, and Inflammation Predict Venous Thromboembolism in Patients with Haematological Malignancies?. Acta Haematologica, 2019, 141, 245-253.	1.4	4
768	Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Annals of Oncology, 2019, 30, 897-907.	1.2	80
769	Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. Journal of Thrombosis and Thrombolysis, 2019, 48, 125-133.	2.1	18
770	Prognostic Factors for Thrombosis in Cancer Patients. Archivos De Bronconeumologia, 2019, 55, 67-68.	0.8	0
772	Identification du risque vasculaire : un audit bioclinique en trois dimensions. Option/Bio, 2019, 30, 15-21.	0.0	0
773	Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. Gastric Cancer, 2019, 22, 988-998.	5.3	18
775	Bevacizumab Plus Direct Oral Anticoagulant Therapy in Ovarian Cancer Patients with Distal Deep Vein Thrombosis. Clinical Drug Investigation, 2019, 39, 395-400.	2.2	6
776	Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants. Thrombosis Research, 2019, 177, 33-41.	1.7	15
777	Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. New England Journal of Medicine, 2019, 380, 781-783.	27.0	59
778	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. New England Journal of Medicine, 2019, 380, 720-728.	27.0	520
779	Review: In patients with cancer, prophylactic anticoagulants reduce VTE and do not increase major bleeding. Annals of Internal Medicine, 2019, 171, JC65.	3.9	1
780	What's new in the prevention and treatment of cancer-associated thrombosis?. Hematology American Society of Hematology Education Program, 2019, 2019, 158-166.	2.5	4
781	Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: a single-institutional retrospective cohort analysis (Sapporo CAT study). BMJ Open, 2019, 9, e028563.	1.9	11

#	ARTICLE	IF	CITATIONS
782	Acute arterial thrombosis during adjuvant Adriamycin-cyclophosphamide chemotherapy in a patient with early breast cancer. <i>Medicine (United States)</i> , 2019, 98, e18249.	1.0	1
783	Prevention and Treatment of Cancer-Associated Venous Thromboembolism: a Review. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 70.	0.9	4
784	Low-Molecular-Weight Heparin in Cancer Patients: Overview and Indications. <i>Hamostaseologie</i> , 2019, 39, 067-075.	1.9	8
785	Thromboembolism and bleeding in patients with cancer and mechanical heart valves. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 454-461.	2.1	1
786	Arterial thromboembolic events preceding the diagnosis of cancer in older persons. <i>Blood</i> , 2019, 133, 781-789.	1.4	127
787	Venous thromboembolism prevention through the use of novel Factor Xa inhibitors. <i>Postgraduate Medicine</i> , 2019, 131, 89-95.	2.0	1
788	In response to: New data for venous thromboembolism in patients with small cell lung cancer: A review. <i>Phlebology</i> , 2019, 34, 137-138.	1.2	0
789	The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. <i>Haematologica</i> , 2019, 104, 1277-1287.	3.5	197
790	Predictive factors for cancer-associated thrombosis in a large retrospective single-center study. <i>Supportive Care in Cancer</i> , 2019, 27, 1163-1170.	2.2	12
791	Risk of Venous Thromboembolism for Patients with Pancreatic Ductal Adenocarcinoma Undergoing Preoperative Chemotherapy Followed by Surgical Resection. <i>Annals of Surgical Oncology</i> , 2019, 26, 1503-1511.	1.5	21
793	Abnormal red blood cell indices increase the risk of arterial ischemic stroke in children. <i>Journal of Clinical Neuroscience</i> , 2019, 62, 117-120.	1.5	4
794	Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 50.	3.7	30
795	Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges. <i>Cancers</i> , 2019, 11, 71.	3.7	30
796	Cyclin-Dependent Kinase Inhibitorâ€Associated Thromboembolism. <i>JAMA Oncology</i> , 2019, 5, 141.	7.1	13
797	Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 711-719.	27.0	614
798	Thrombosis and Cancer. , 2019, , 430-447.		0
799	Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. <i>Internal and Emergency Medicine</i> , 2019, 14, 21-38.	2.0	13
800	A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer â€A real world experience. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 793-800.	0.9	12

#	ARTICLE	IF	CITATIONS
801	The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients: A 9-year single-center experience. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 386-396.	0.9	5
802	Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients. <i>Haematologica</i> , 2020, 105, 838-848.	3.5	21
803	Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors. <i>Haematologica</i> , 2020, 105, 218-225.	3.5	117
804	Risk factors for venous thromboembolism in hospitalized patients with hematological malignancy: an analysis of the National Inpatient Sample, 2011-2015. <i>Leukemia and Lymphoma</i> , 2020, 61, 370-376.	1.3	4
805	Multi-Objective Optimization for Personalized Prediction of Venous Thromboembolism in Ovarian Cancer Patients. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 1500-1508.	6.3	14
806	Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 411-421.	3.8	381
807	Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. <i>European Journal of Haematology</i> , 2020, 104, 88-96.	2.2	24
808	Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients. <i>Journal of Cardiology</i> , 2020, 75, 110-114.	1.9	15
809	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 496-520.	1.6	971
810	Predicting venous thrombosis in patients undergoing elective splenectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 2191-2196.	2.4	8
811	2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.	2.2	2,426
812	Modified neutrophil-platelet score as a promising marker for stratified surgical and oncological outcomes of patients with gastric cancer. <i>Surgery Today</i> , 2020, 50, 223-231.	1.5	5
813	Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. <i>European Urology</i> , 2020, 77, 388-390.	1.9	3
814	Cancer-associated thrombosis: Where do we stand?. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e73.	0.9	4
815	Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188331.	7.4	12
816	Association between the Khorana score and pulmonary embolism risk in patients with advanced stage lung cancer. <i>Clinical Respiratory Journal</i> , 2020, 14, 3-8.	1.6	6
817	Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 162-168.	3.8	55
818	Prevention of Venous Thromboembolism in Pancreatic Cancer: Breaking Down a Complex Clinical Dilemma. <i>Oncologist</i> , 2020, 25, 132-139.	3.7	15

#	ARTICLE	IF	CITATIONS
819	Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin. <i>Clinical and Translational Oncology</i> , 2020, 22, 1312-1320.	2.4	1
820	Development of a Clinical Prediction Rule for Venous Thromboembolism in Patients with Acute Leukemia. <i>Thrombosis and Haemostasis</i> , 2020, 120, 322-328.	3.4	17
821	Black Patients Experience Highest Rates of Cancer-associated Venous Thromboembolism. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 94-100.	1.3	16
822	Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). <i>Cancer Medicine</i> , 2020, 9, 116-124.	2.8	17
823	Development of a clinical prediction tool for cancer-associated venous thromboembolism (CAT): the MD Anderson Cancer Center CAT model. <i>Supportive Care in Cancer</i> , 2020, 28, 3755-3761.	2.2	9
824	Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 1200-1206.	2.6	52
825	Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. <i>Gastroenterology</i> , 2020, 158, 1346-1358.e4.	1.3	48
826	Diagnosis, Treatment, and Prevention of Cancer-Associated Thrombosis. , 2020, , 523-543.e7.		1
827	Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 651-659.	3.8	19
829	Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2020, 12, 67.	3.7	39
830	Paraneoplastic Thromboembolism and Thrombophilia: Significance in Visceral Medicine. <i>Visceral Medicine</i> , 2020, 36, 280-287.	1.3	6
831	Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 90-92.	0.2	1
832	D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer. <i>Oncologist</i> , 2020, 25, 1075-1083.	3.7	9
833	High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score. <i>Thrombosis Research</i> , 2020, 196, 349-354.	1.7	16
834	Management of Cancer-Associated Thrombosis: An Evolving Area. <i>Cancers</i> , 2020, 12, 2999.	3.7	1
835	Increased D-dimer predicts the risk of cancer-associated recurrent venous thromboembolism and venous thromboembolism: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020, 196, 410-413.	1.7	4
836	Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1211-1215.	2.3	17
837	Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer. <i>Thrombosis Research</i> , 2020, 196, 437-443.	1.7	0

#	ARTICLE	IF	CITATIONS
838	Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia. The Cochrane Library, 2020, 10, CD013399.	2.8	6
840	The risk factors for perioperative venous thromboembolism in patients with gynecological malignancies: A meta-analysis. Thrombosis Research, 2020, 196, 325-334.	1.7	7
841	Thromboembolic events in brain tumour patients on bevacizumab. Acta Oncol ³ gica, 2020, 59, 1543-1546.	1.8	2
842	Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?. Cancers, 2020, 12, 1907.	3.7	5
843	Dynamics of D-dimer in non-small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism. Thoracic Cancer, 2020, 11, 2483-2492.	1.9	10
844	Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective Analysis. Cancers, 2020, 12, 1711.	3.7	1
845	Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. Cancer Medicine, 2020, 9, 6196-6204.	2.8	20
846	A risk score for prediction of venous thromboembolism in gynecologic cancer: The Thrombogyn score. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 848-859.	2.3	13
847	New insights on patient-related risk factors for venous thromboembolism in patients with solid organ cancers. International Journal of Hematology, 2020, 112, 477-486.	1.6	4
850	Von Willebrand factor:antigen and ADAMTS-13 level, but not soluble P-selectin, are risk factors for the first asymptomatic deep vein thrombosis in cancer patients undergoing chemotherapy. Thrombosis Journal, 2020, 18, 33.	2.1	9
851	Risk factors for venous thromboembolism and evaluation of the modified Caprini score in patients undergoing lung resection. Journal of Thoracic Disease, 2020, 12, 4805-4816.	1.4	11
852	<p>>The Influence of Venous Characteristics on Peripherally Inserted Central Catheter-Related Symptomatic Venous Thrombosis in Cancer Patients<p>>. Cancer Management and Research, 2020, Volume 12, 11909-11920.	1.9	8
853	Epidemiology and risk factors for cancer-associated thrombosis. JMV-Journal De Medecine Vasculaire, 2020, 45, 6S3-6S7.	0.2	6
854	Cancer and thrombosis: new insights to an old problem. JMV-Journal De Medecine Vasculaire, 2020, 45, 6S8-6S16.	0.2	22
855	Validation of the IMPROVE bleeding risk score in Chinese medical patients during hospitalization: Findings from the dissolve-2 study. The Lancet Regional Health - Western Pacific, 2020, 4, 100054.	2.9	3
856	Prevention of venous thromboembolism in ambulatory patients with cancer. ESMO Open, 2020, 5, e000948.	4.5	16
857	SARS-CoV-2 Infection and Cardioncology: From Cardiometaabolic Risk Factors to Outcomes in Cancer Patients. Cancers, 2020, 12, 3316.	3.7	23
858	Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients. Frontiers in Cardiovascular Medicine, 2020, 7, 571227.	2.4	5

#	ARTICLE	IF	CITATIONS
859	Inpatient prophylaxis in cancer patients: where is the evidence?. Thrombosis Research, 2020, 191, S85-S90.	1.7	3
860	Latest advances in preventing thromboembolic disease in the ambulatory oncology patient. Thrombosis Research, 2020, 191, S91-S98.	1.7	2
861	Peripherally Inserted Central Catheter lines for Intensive Care Unit and onco-hematologic patients: A systematic review and meta-analysis. Heart and Lung: Journal of Acute and Critical Care, 2020, 49, 922-933.	1.6	5
862	Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients. Cancers, 2020, 12, 1958.	3.7	21
863	Venous thromboembolism during preoperative chemotherapy in the CRITICS gastric cancer trial. Cancer Medicine, 2020, 9, 6609-6616.	2.8	8
864	Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer. Thrombosis Research, 2020, 191, S50-S57.	1.7	13
865	Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer. Cancers, 2020, 12, 2070.	3.7	7
866	Genes and proteins associated with the risk for cancer-associated thrombosis. Thrombosis Research, 2020, 191, S43-S49.	1.7	6
867	Thrombosis in hematological malignancies: mechanisms and implications. Thrombosis Research, 2020, 191, S58-S62.	1.7	14
868	Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event. Journal of Thrombosis and Haemostasis, 2020, 18, 2861-2869.	3.8	11
869	Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers, 2020, 12, 2028.	3.7	17
870	Prevention of Venous Thromboembolism in 2020 and Beyond. Journal of Clinical Medicine, 2020, 9, 2467.	2.4	82
871	Assessing the risk of venous thromboembolism in multiple myeloma. Thrombosis Research, 2020, 191, S74-S78.	1.7	8
872	Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis. Thrombosis Research, 2020, 191, S79-S84.	1.7	22
873	Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future. Thrombosis Research, 2020, 191, S3-S11.	1.7	26
874	Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study. Thrombosis Research, 2020, 191, S31-S36.	1.7	10
875	Reconsidering the GAVECeLT Consensus on catheter-related thrombosis, 13 years later. Journal of Vascular Access, 2021, 22, 501-508.	0.9	15
876	COVID-19 and Cardiovascular Health Among Patients with Cancer. Current Cardiology Reports, 2020, 22, 171.	2.9	8

#	ARTICLE	IF	CITATIONS
877	Prognostic Impact of Coagulation Activity in Patients Undergoing Curative Resection for Pancreatic Ductal Adenocarcinoma. <i>In Vivo</i> , 2020, 34, 2845-2850.	1.3	4
878	A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. <i>European Urology Focus</i> , 2021, 7, 1130-1136.	3.1	13
879	Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 5215-5225.	5.2	35
880	Patterns and predictors of thromboembolic events among patients with gastric cancer. <i>Scientific Reports</i> , 2020, 10, 18516.	3.3	8
881	Randomized Controlled Trials Versus Real-World Data in the COVID-19 Era: A False Narrative. <i>Cancer Investigation</i> , 2020, 38, 537-542.	1.3	7
882	Development of a Model for Predicting Early Discontinuation of Adjuvant Chemotherapy in Stage III Colon Cancer. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 972-984.	2.1	4
883	Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3267-3279.	3.8	4
884	Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels. <i>Cancer Medicine</i> , 2020, 9, 8062-8073.	2.8	23
885	Central Venous Catheter Thrombosis in Cancer: A Multi-Centre Retrospective Study Investigating Risk Factors and Contemporary Trends in Management. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492095309.	1.3	13
886	Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 997-1003.	2.3	8
888	Association of Inferior Vena Cava Filter Placement With Rates of Pulmonary Embolism in Patients With Cancer and Acute Lower Extremity Deep Venous Thrombosis. <i>JAMA Network Open</i> , 2020, 3, e2011079.	5.9	26
889	Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 31, 454-460.	1.1	5
890	Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962095428.	1.7	32
891	Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. <i>The Cochrane Library</i> , 2020, 2020, CD008500.	2.8	18
892	Prevalence of Venous Thromboembolism in Kumasi: A Postmortem-Based Study in a Tertiary Hospital in Ghana. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2020, 14, 117954842095636.	0.9	1
893	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 568720.	2.4	5
894	Venous thromboembolism in multiple myeloma is associated with increased mortality. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1203-1210.	2.3	19
895	Debate: Thromboprophylaxis should be considered in all patients with cancer - No. <i>Thrombosis Research</i> , 2020, 191, 34-35.	1.7	2

#	ARTICLE	IF	CITATIONS
896	Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey. <i>Oncologist</i> , 2020, 25, e1091-e1097.	3.7	10
897	Thromboembolic and bleeding complications in patients with oesophageal cancer. <i>British Journal of Surgery</i> , 2020, 107, 1324-1333.	0.3	4
898	Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care. <i>Cancers</i> , 2020, 12, 1167.	3.7	5
899	Thromboprophylaxis in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020, 190, 493-494.	2.5	0
900	Prevention and Treatment of Thromboembolic Events in Patients with Cancer: Advances and Challenges. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 124-127.	5.6	0
901	Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.	1.5	18
902	Aspirin Is Associated With Reduced Rates of Venous Thromboembolism in Older Patients With Cancer. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 456-465.	2.0	14
903	Debate: Thromboprophylaxis should be considered in all patients with cancer â€“ Yes. <i>Thrombosis Research</i> , 2020, 191, 142-144.	1.7	3
904	Venous thromboembolic events in patients with brain metastases: the PICOS score. <i>European Journal of Cancer</i> , 2020, 134, 75-85.	2.8	11
905	Clinical and Cancer-Related Predictors for Venous Thromboembolism in Cancer Patients Presenting to the Emergency Department. <i>Journal of Emergency Medicine</i> , 2020, 58, 932-941.	0.7	6
906	Incidence, Therapy, and Bleeding Riskâ€”Cancer- Associated Thrombosis in Patients with Glioblastoma. <i>Cancers</i> , 2020, 12, 1354.	3.7	9
907	Acute ischaemic stroke following cisplatin-based chemotherapy for testicular cancer. <i>BMJ Case Reports</i> , 2020, 13, e235005.	0.5	7
908	Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. <i>Blood Advances</i> , 2020, 4, 2254-2260.	5.2	22
909	Thromboembolic events after highâ€”intensity training during cisplatinâ€”based chemotherapy for testicular cancer: Case reports and review of the literature. <i>International Journal of Cancer</i> , 2020, 147, 3189-3198.	5.1	11
910	Venous Thromboembolism During Chemotherapy for Testicular Cancer: A Population-Based Study. <i>Clinical Oncology</i> , 2020, 32, e188-e193.	1.4	6
911	Advances in the Diagnosis of Venous Thromboembolism: A Literature Review. <i>Diagnostics</i> , 2020, 10, 365.	2.6	19
912	Dynamic prediction modeling for cancerâ€”associated venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1276-1277.	3.8	1
913	The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 542-547.	0.4	8

#	ARTICLE	IF	CITATIONS
915	Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 636-643.	2.3	23
916	The TICONC (Ticagrelor-Oncology) Study. <i>JACC: CardioOncology</i> , 2020, 2, 236-250.	4.0	15
917	microRNAs and Markers of Neutrophil Activation as Predictors of Early Incidental Post-Surgical Pulmonary Embolism in Patients with Intracranial Tumors. <i>Cancers</i> , 2020, 12, 1536.	3.7	15
919	Do we need prophylactic anticoagulation in ambulatory patients with lung cancer? A review. <i>Vascular Medicine</i> , 2020, 25, 255-262.	1.5	3
920	Thromboprophylaxis in the End-of-Life Cancer Care: The Update. <i>Cancers</i> , 2020, 12, 600.	3.7	7
921	Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. <i>Cancers</i> , 2020, 12, 618.	3.7	16
922	Preventing Venous Thromboembolism in Ambulatory Patients with Cancer: A Narrative Review. <i>Cancers</i> , 2020, 12, 612.	3.7	5
923	Rivaroxaban <i>versus</i> Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer. <i>In Vivo</i> , 2020, 34, 829-837.	1.3	10
924	Mechanisms and biomarkers of cancer-associated thrombosis. <i>Translational Research</i> , 2020, 225, 33-53.	5.0	50
925	Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 479-487.	2.5	30
926	Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients. <i>Oncology Research and Treatment</i> , 2020, 43, 414-427.	1.2	11
927	Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 267-277.	2.1	54
928	Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	3.2	6
929	Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?. <i>Cancers</i> , 2020, 12, 367.	3.7	15
930	Prospective evaluation of drug–drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1637-1642.	0.9	7
931	Predictors of venous thromboembolism development before and during chemotherapy for advanced germ cell tumor. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 338-343.	1.3	2
932	Cancer-Related Venous Thromboembolism as a Complication and Negative Prognostic Factor. <i>Gastroenterology</i> , 2020, 158, 1214-1215.	1.3	1
933	RNA expression and risk of venous thromboembolism in lung cancer. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 117-123.	2.3	9

#	ARTICLE	IF	CITATIONS
934	High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08. BMC Cancer, 2020, 20, 166.	2.6	2
935	Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). JMV-Journal De Medecine Vasculaire, 2020, 45, 28-40.	0.2	3
936	Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Internal Medicine Journal, 2020, 50, 1475-1482.	0.8	16
937	Prevention of thrombosis. , 2020, , 59-104.		0
938	Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. Cancers, 2020, 12, 191.	3.7	48
939	SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clinical and Translational Oncology, 2020, 22, 171-186.	2.4	32
940	Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States. Journal of Thrombosis and Thrombolysis, 2020, 50, 386-394.	2.1	15
941	Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies. Leukemia and Lymphoma, 2020, 61, 1277-1291.	1.3	7
942	Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. FASEB Journal, 2020, 34, 4204-4218.	0.5	70
943	Risk of venous thromboembolism in patients undergoing gastric cancer surgery: protocol for a systematic review and meta-analysis. BMJ Open, 2020, 10, e033267.	1.9	2
944	Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental. Anticancer Research, 2020, 40, 305-313.	1.1	8
945	Outcomes after venous thromboembolism in patients with gastric cancer: Analysis of the RIETE Registry. Vascular Medicine, 2020, 25, 210-217.	1.5	4
946	Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy. Clinical Genitourinary Cancer, 2020, 18, e457-e472.	1.9	3
947	MicroRNAs and Neutrophil Activation Markers Predict Venous Thrombosis in Pancreatic Ductal Adenocarcinoma and Distal Extrahepatic Cholangiocarcinoma. International Journal of Molecular Sciences, 2020, 21, 840.	4.1	28
948	External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model. Oncologist, 2020, 25, e1083-e1090.	3.7	19
949	ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer—A Retrospective Analysis. Oncologist, 2020, 25, e284-e290.	3.7	19
950	Pharmacological cancer treatment and venous thromboembolism risk. European Heart Journal Supplements, 2020, 22, C2-C14.	0.1	11
951	A pilot study of adjuvant chemotherapy with carboplatin and oral Sâ€1 for patients with completely resected stage II to IIIA nonâ€small cell lung cancer. Thoracic Cancer, 2020, 11, 1633-1638.	1.9	0

#	ARTICLE	IF	CITATIONS
952	Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy. <i>Lung</i> , 2020, 198, 575-579.	3.3	5
954	Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status. <i>Clinical and Translational Oncology</i> , 2020, 22, 2026-2031.	2.4	8
955	Risk assessment of venous thromboembolism in hematological cancer patients: a review. <i>Expert Review of Hematology</i> , 2020, 13, 471-480.	2.2	4
956	Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?. <i>Cancers</i> , 2020, 12, 917.	3.7	11
957	Venous Thromboembolism Treatment and Prevention in Cancer Patients: Can We Use Pills Yet?. <i>Current Treatment Options in Oncology</i> , 2020, 21, 43.	3.0	1
958	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	3.8	60
959	Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. <i>Blood Advances</i> , 2020, 4, 1746-1755.	5.2	17
960	Epidemiology of Venous Thromboembolism After Second Cancer. <i>Clinical Epidemiology</i> , 2020, Volume 12, 377-386.	3.0	2
961	Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma-specific venous thrombosis prediction models. <i>American Journal of Hematology</i> , 2020, 95, 918-926.	4.1	8
962	Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 532-549.	2.3	10
963	Successful Model for Guideline Implementation to Prevent Cancer-Associated Thrombosis: Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic. <i>JCO Oncology Practice</i> , 2020, 16, e868-e874.	2.9	28
964	Could Preoperative Unintended Weight Loss Predispose to Postoperative Thrombosis in Patients Undergoing Colorectal Cancer Surgery? An Analysis of the NSQIP Data. <i>Journal of the American College of Nutrition</i> , 2021, 40, 141-147.	1.8	3
965	A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place. <i>Journal of Neurology</i> , 2021, 268, 2390-2401.	3.6	4
966	Development and validation of a risk assessment nomogram for venous thromboembolism associated with hospitalized postoperative Chinese breast cancer patients. <i>Journal of Advanced Nursing</i> , 2021, 77, 473-483.	3.3	8
967	Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy. <i>Supportive Care in Cancer</i> , 2021, 29, 1699-1709.	2.2	6
968	Anticoagulation reduces ilioaval and iliofemoral stent thrombosis in patients with cancer stented for nonthrombotic venous obstruction. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 88-94.	1.6	6
969	In vitro real-time magnetic resonance imaging for quantification of thrombosis. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2021, 34, 285-295.	2.0	16
970	Ethnoracial variations in venous thrombosis: Implications for management, and a call to action. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 30-40.	3.8	8

#	ARTICLE	IF	CITATIONS
971	Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement. <i>Gynecologic Oncology</i> , 2021, 160, 312-321.	1.4	15
972	Update on Guidelines for the Management of Cancer-Associated Thrombosis. <i>Oncologist</i> , 2021, 26, e24-e40.	3.7	76
973	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1245-1252.	2.4	21
974	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. <i>Blood</i> , 2021, 137, 2103-2113.	1.4	57
975	Prediction and Prevention of Cancer-Associated Thromboembolism. <i>Oncologist</i> , 2021, 26, e2-e7.	3.7	33
976	Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, Japan. <i>International Journal of Clinical Oncology</i> , 2021, 26, 485-493.	2.2	32
977	An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 583-594.	1.8	4
978	Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103125.	4.4	11
979	Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence. <i>Clinical and Translational Oncology</i> , 2021, 23, 1034-1046.	2.4	3
980	Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103193.	4.4	12
981	Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System Lymphoma. <i>Oncology Research and Treatment</i> , 2021, 44, 52-57.	1.2	2
982	A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 711-719.	2.1	5
983	Progress in the study of cancer-associated venous thromboembolism. <i>Vascular</i> , 2021, 29, 408-414.	0.9	4
984	Variation of red blood cell parameters in Behçet's disease: association with disease severity and vascular involvement. <i>Clinical Rheumatology</i> , 2021, 40, 1457-1464.	2.2	7
985	Update on extended prophylaxis for venous thromboembolism following surgery for gynaecological cancers. <i>Thrombosis Update</i> , 2021, 2, 100038.	0.9	3
986	Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: Risk Factors and Prevention. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 914-919.	2.7	7
987	Direct Oral Anticoagulation in Cancer Patients. , 2021, , 179-198.		0
988	Cardiovascular Oncologic Emergencies. , 2021, , 269-290.		0

#	ARTICLE	IF	CITATIONS
989	Predictors of Venous Thromboembolism in Patients With Testicular Germ Cell Tumors: A Retrospective Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110247.	1.7	3
990	Thrombotic risk in gastroenteropancreatic neuroendocrine tumor patients: a single-center experience. <i>Annals of Gastroenterology</i> , 2021, 34, 588-593.	0.6	0
991	The Clinical Aspects of Heart Damage by Chemotherapy and Radiotherapy. , 2021, , 675-689.		0
992	The prothrombotic state in cancer. <i>Advances in Clinical Chemistry</i> , 2021, 105, 213-242.	3.7	2
993	Utilization and Complications of Central Venous Access Devices in Oncology Patients. <i>Current Oncology</i> , 2021, 28, 367-377.	2.2	14
994	Clinical Presentation and Symptoms in Pancreatic Cancer. , 2021, , 357-368.		0
995	Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. , 2021, 9, e001719.		62
996	LMWH Treatment in Patients with Cancer Diagnosed with Venous Thromboembolism. <i>Journal of Indonesian Society for Vascular and Endovascular Surgery</i> , 2021, 2, 26-29.	0.0	0
998	Advances in the Management of Cancer-Associated Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 139-149.	2.7	16
999	The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. <i>Surgery Today</i> , 2021, 51, 1480-1487.	1.5	5
1000	Prognostic impact and risk factors of cancer-associated thrombosis events in stage IV cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Haematology</i> , 2021, 106, 682-688.	2.2	21
1001	A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 898-903.	2.1	7
1002	The risk of venous thromboembolism in cancer patients receiving chemotherapy: a meta-analysis with systematic review. <i>Annals of Translational Medicine</i> , 2021, 9, 277-277.	1.7	5
1003	Effect of occult malignancy on femoropopliteal bypass graft thrombosis. <i>Journal of Vascular Surgery</i> , 2021, 74, 514-520.e2.	1.1	3
1004	The incidence and risk factors for venous thromboembolism in adolescent and young adult oncology patients. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28957.	1.5	3
1005	American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. <i>Blood Advances</i> , 2021, 5, 927-974.	5.2	431
1006	Validation of the IMPROVE risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 296-300.	2.3	34
1007	Etiology of Cancer Associated Thromboembolism (CAT), and Diet, Lifestyle and Medicine to Reduce Cancer and Venous Thromboembolism. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1008	CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. <i>European Journal of Haematology</i> , 2021, 106, 634-642.	2.2	28
1009	High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations. <i>Translational Lung Cancer Research</i> , 2021, 10, 1512-1524.	2.8	13
1010	Cancer-Associated Venous Thromboembolism in Ambulatory Solid Organ Malignancy Patients: Experience from a Cancer Research Institute. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 246-250.	0.7	0
1011	Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy. <i>World Journal of Clinical Oncology</i> , 2021, 12, 183-194.	2.3	2
1012	Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients. <i>Thrombosis Research</i> , 2021, 199, 21-31.	1.7	1
1013	Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 617966.	2.8	14
1014	Early venous thromboembolism is a strong prognostic factor in patients with advanced pancreatic ductal adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3447-3454.	2.5	6
1015	Incidence and Risk of Various Types of Arterial Thromboembolism in Patients With Cancer. <i>Mayo Clinic Proceedings</i> , 2021, 96, 592-600.	3.0	14
1016	Vascular Imaging in the Asymptomatic <scp>High-risk</scp> Cancer Population. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 225-236.	1.7	1
1017	Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1250-1258.	3.8	34
1018	Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 911-918.	0.9	2
1019	Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy. <i>Supportive Care in Cancer</i> , 2021, 29, 5417-5423.	2.2	15
1020	Incidence and risk factors of VTE in patients with cervical cancer using the Korean national health insurance data. <i>Scientific Reports</i> , 2021, 11, 8031.	3.3	1
1021	Arterial Thromboembolism in Cancer Patients. <i>JACC: CardioOncology</i> , 2021, 3, 205-218.	4.0	33
1022	Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 634291.	2.4	6
1023	Increased incidence of venous thromboembolism with cancer immunotherapy. <i>Med</i> , 2021, 2, 423-434.e3.	4.4	46
1025	Venous and Arterial Thromboembolism in Patients With Cancer. <i>JACC: CardioOncology</i> , 2021, 3, 173-190.	4.0	67
1026	The Clinical Applicability of Primary Thromboprophylaxis in Ambulatory Patients With Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 494-499.	1.1	1

#	ARTICLE	IF	CITATIONS
1027	Sticky Issues: What APs Need to Know About Anticoagulants and Patients With Cancer. Journal of the Advanced Practitioner in Oncology, 2021, 12, 262-265.	0.4	0
1028	Cancer and Clot. JACC: CardioOncology, 2021, 3, 219-220.	4.0	1
1029	Anticoagulation in Patients with Platelet Disorders. Hamostaseologie, 2021, 41, 112-119.	1.9	3
1030	Outpatient treatment of emergency department patients diagnosed with venous thromboembolism. Postgraduate Medicine, 2021, 133, 11-19.	2.0	2
1031	Highlights from the American society of hematology conference 2020. Journal of Thrombosis and Thrombolysis, 2021, 52, 354-362.	2.1	0
1032	Upper Extremity Deep Vein Thrombosis: Current Knowledge and Future Directions. Seminars in Thrombosis and Hemostasis, 2021, 47, 677-691.	2.7	4
1033	Burden of venous thromboembolism in patients with pancreatic cancer. World Journal of Gastroenterology, 2021, 27, 2325-2340.	3.3	6
1034	Incidence and risk factors for venous thromboembolism in a cohort of Taiwanese patients with lung, gastric, pancreatic cancers or lymphoma. Journal of the Formosan Medical Association, 2022, 121, 360-366.	1.7	5
1035	A Nomogram for Predicting Risk of Thromboembolism in Gastric Cancer Patients Receiving Chemotherapy. Frontiers in Oncology, 2021, 11, 598116.	2.8	6
1036	Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer. Cardio-Oncology, 2021, 7, 20.	1.7	8
1037	Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review. Frontiers in Cardiovascular Medicine, 2021, 8, 669288.	2.4	20
1038	Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study. Bladder Cancer, 2021, 7, 161-171.	0.4	1
1039	Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index. Risk Management and Healthcare Policy, 2021, Volume 14, 1855-1867.	2.5	1
1040	A novel nomogram based on prognostic factors for predicting venous thrombosis risk in lymphoma patients. Leukemia and Lymphoma, 2021, 62, 2383-2391.	1.3	6
1041	Cancer-Associated Thrombosis: A New Light on an Old Story. Diseases (Basel, Switzerland), 2021, 9, 34.	2.5	8
1042	The Application of the Lymphoma International Prognostic Index to Predict Venous Thromboembolic Events in Diffuse Large B-Cell Lymphoma Patients. Frontiers in Oncology, 2021, 11, 677776.	2.8	8
1043	Cancer-Related Venous Thromboembolism: From Pathogenesis to Risk Assessment. Seminars in Thrombosis and Hemostasis, 2021, 47, 669-676.	2.7	8
1045	Incidence of venous thromboembolism in patients with solid cancers in Japan: retrospective study of 2735 patients. International Journal of Hematology, 2021, 114, 319-324.	1.6	2

#	ARTICLE	IF	CITATIONS
1046	Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial. <i>Thrombosis Research</i> , 2021, 202, 151-154.	1.7	11
1047	Validation of the Khorana Score for Prediction of Venous Thromboembolism After Robot-Assisted Radical Cystectomy. <i>Journal of Endourology</i> , 2021, 35, 821-827.	2.1	2
1048	Venous Thromboembolism in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian Cancer and Impact on Survival. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2021, 43, 1380-1387.	0.7	8
1049	Risk Assessment Models for Thrombosis and Anticoagulant-Related Bleeding in Ambulatory Cancer Patients. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 972-981.	2.7	6
1050	Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (Ä-GHO). <i>Cancers</i> , 2021, 13, 2905.	3.7	7
1051	Current Recommendations for the Management of Cancer-Associated Venous Thromboembolism. <i>Journal of Cardiovascular Emergencies</i> , 2021, 7, 27-38.	0.2	0
1052	Venous thromboembolism in patients with severe lung cancer: a narrative review. <i>Annals of Palliative Medicine</i> , 2021, 10, 6957-6967.	1.2	5
1053	Cancer and Thrombosis: New Treatments, New Challenges. <i>Medical Sciences (Basel, Switzerland)</i> , 2021, 9, 41.	2.9	4
1054	Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 202-207.	2.1	8
1055	Thrombosis and myeloma: it is time to get the elephant out of the room. <i>British Journal of Haematology</i> , 2021, 193, 1027-1029.	2.5	0
1057	Cardiovascular events in cancer patients with bone metastases—A Danish population-based cohort study of 23,113 patients. <i>Cancer Medicine</i> , 2021, 10, 4885-4895.	2.8	6
1058	Thromboembolic risk in patients with lung cancer receiving systemic therapy. <i>British Journal of Haematology</i> , 2021, 194, 179-190.	2.5	9
1059	Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. <i>Thrombosis Research</i> , 2021, 202, 128-133.	1.7	9
1060	Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer. <i>Healthcare (Switzerland)</i> , 2021, 9, 778.	2.0	5
1061	Reliability and validity of D-dimer monitoring for pulmonary thromboembolism in patients with unresectable, advanced or recurrent colorectal cancer treated with bevacizumab. <i>Molecular and Clinical Oncology</i> , 2021, 15, 165.	1.0	1
1062	Use of antithrombotics at the end of life: an in-depth chart review study. <i>BMC Palliative Care</i> , 2021, 20, 110.	1.8	7
1063	Thrombophilia identified as a risk factor for thrombogenesis in cancer patients. <i>Obstetrics, Gynecology and Reproduction</i> , 2021, 15, 228-235.	0.5	0
1064	Racial differences in symptomatic postoperative venous thromboembolism rates after major oncologic resection. <i>Surgery</i> , 2021, 170, 1770-1776.	1.9	1

#	ARTICLE	IF	CITATIONS
1065	Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies. International Journal of General Medicine, 2021, Volume 14, 3881-3897.	1.8	11
1066	Venous thromboembolism. Lancet, The, 2021, 398, 64-77.	13.7	243
1068	Prognostic Factors for Venous Thromboembolism in Patients with Solid Tumours on Systemic Therapy: A Systematic Review. TH Open, 2021, 05, e461-e469.	1.4	0
1069	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. Gynecologic Oncology, 2021, 163, 36-40.	1.4	18
1070	Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. International Journal of Gynecological Cancer, 2021, 31, 1348-1355.	2.5	3
1071	Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. Blood Advances, 2021, 5, 4102-4111.	5.2	10
1072	Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Cancer Science, 2021, 112, 4679-4691.	3.9	20
1073	Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol. Gynecologic Oncology, 2021, 162, 353-359.	1.4	9
1074	Central catheter-associated deep vein thrombosis in cancer: clinical course, prophylaxis, treatment. BMJ Supportive and Palliative Care, 2021, 11, 371-380.	1.6	17
1075	Primary diffuse large B-cell lymphoma of the cranial vault with Trousseau syndrome: a case report. Journal of Medical Case Reports, 2021, 15, 431.	0.8	3
1076	A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment. Postgraduate Medicine, 2021, 133, 71-79.	2.0	6
1077	Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment. Global Health & Medicine, 2021, 3, 214-225.	1.4	9
1078	Validation of Risk-Adapted Venous Thromboembolism Prediction in Multiple Myeloma Patients. Journal of Clinical Medicine, 2021, 10, 3536.	2.4	5
1079	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 857-873.	17.8	56
1080	The COVID-19 risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. Journal of Thrombosis and Haemostasis, 2021, 19, 2522-2532.	3.8	23
1081	Cost-Effectiveness of Venous Thromboembolism Prophylaxis During Neoadjuvant Chemotherapy for Ovarian Cancer. JCO Oncology Practice, 2021, 17, e1075-e1084.	2.9	10
1082	Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia. , 2021, 9, e002332.		8
1083	Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma. Gynecologic Oncology, 2021, 163, 327-333.	1.4	5

#	ARTICLE	IF	CITATIONS
1084	Risk of arterial and venous thromboembolic events among patients with colorectal carcinoma: a real-world, population-based study. <i>Future Oncology</i> , 2021, 17, 3977-3986.	2.4	3
1085	Risk assessment of thromboembolic events in hospitalized cancer patients. <i>Scientific Reports</i> , 2021, 11, 18200.	3.3	5
1086	Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database. <i>International Immunopharmacology</i> , 2021, 98, 107818.	3.8	12
1087	Venous thromboembolism in women with ovarian cancer undergoing neoadjuvant chemotherapy prior to cytoreductive surgery: A retrospective study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 2091-2096.	2.8	8
1088	Increased Incidence of Thrombotic Complications With Non-small Cell Lung Cancer Necessitates Consideration of Prophylactic Anticoagulation in Young Individuals. <i>Cureus</i> , 2021, 13, e17769.	0.5	3
1089	Risk Assessment for Cancer-Associated VTE. <i>JACC Asia</i> , 2021, 1, 271-273.	1.5	2
1090	Association of smoking and cancer with the risk of venous thromboembolism: the Scandinavian Thrombosis and Cancer cohort. <i>Scientific Reports</i> , 2021, 11, 18752.	3.3	6
1091	Neo-adjuvant chemotherapy and its anaesthetic implications for surgery—a narrative review. <i>Digestive Medicine Research</i> , 0, 4, 55-55.	0.2	0
1092	The application of “Omics” to accelerate precision medicine in Supportive Care in Cancer. <i>Supportive Care in Cancer</i> , 2021, 29, 7143-7144.	2.2	2
1093	Impact of the mutation profile on thrombotic risk in cancer patients. <i>Revista Clínica Espanola</i> , 2021, 222, 93-93.	0.5	0
1094	Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 1-5.	0.5	0
1095	One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: Results from the Cancer-VTE Registry. <i>Thrombosis Research</i> , 2022, 213, 203-213.	1.7	12
1096	Risk assessment models of cancer-associated thrombosis - Potentials and perspectives. <i>Thrombosis Update</i> , 2021, 5, 100075.	0.9	11
1097	How I treat and prevent venous thrombotic complications in patients with lymphoma. <i>Blood</i> , 2022, 139, 1489-1500.	1.4	5
1098	Evaluation of the Khorana, PROTECHT, and 5aSNP scores for prediction of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2974-2983.	3.8	14
1099	Validation of the Khorana Venous Thromboembolism Risk Score in Japanese Cancer Patients. <i>JACC Asia</i> , 2021, 1, 259-270.	1.5	8
1100	Risk factors of recurrence in patients with cancer-associated venous thromboembolism. <i>European Journal of Internal Medicine</i> , 2021, 91, 98-101.	2.2	1
1101	Risk of Thrombo-Embolic Events in Ovarian Cancer: Does Bevacizumab Tilt the Scale? A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 4603.	3.7	10

#	ARTICLE	IF	CITATIONS
1102	Predictors for thromboembolism in patients with cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2415-2426.	2.5	6
1103	Prognostic Factors for Venous Thromboembolism in Patients with Solid Tumours on Systemic Therapy: A Systematic Review. TH Open, 2021, 05, e461-e469.	1.4	0
1104	Oncologists' attitudes towards prophylaxis of cancer associated venous thromboembolism: A prospective, descriptive study. Journal of Oncology Pharmacy Practice, 2021, , 107815522110357.	0.9	3
1105	A novel hierarchical machine learning model for hospital-acquired venous thromboembolism risk assessment among multiple-departments. Journal of Biomedical Informatics, 2021, 122, 103892.	4.3	9
1106	Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study. European Urology Open Science, 2021, 32, 19-27.	0.4	10
1107	Update on the role of circulating tumour cells in cancer-associated thrombosis. Thrombosis Update, 2021, 5, 100066.	0.9	1
1108	Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma. Journal of Cancer, 2021, 12, 2295-2316.	2.5	26
1109	Cost-Effective Machine Learning Based Clinical Pre-Test Probability Strategy for DVT Diagnosis in Neurological Intensive Care Unit. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110086.	1.7	8
1112	Healthcare costs of patients with cancer stratified by Khorana score risk levels. Journal of Medical Economics, 2021, 24, 866-873.	2.1	1
1113	The Application of the ThroLy Risk Assessment Model to Predict Venous Thromboembolism in Patients with Diffuse Large B-Cell Lymphoma. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110459.	1.7	2
1115	Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer, 2020, 126, 1736-1748.	4.1	23
1116	Chemotherapy-Associated Thrombosis. Cancer Treatment and Research, 2009, 148, 181-206.	0.5	8
1117	Risk Factors for Thrombosis in Cancer Patients. Cancer Treatment and Research, 2009, 148, 95-114.	0.5	4
1118	Outline: Pediatric Venous Thromboembolism. , 2017, , 205-223.		1
1119	Determination of a Matrix of the Dependencies Between Features Based on the Expert Knowledge. Lecture Notes in Computer Science, 2018, , 570-578.	1.3	4
1120	Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. , 2019, 22, 988.		1
1121	Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1497-1506.	1.1	46
1122	Management of cancer-associated venous thromboembolism - a case-based practical approach. Vasa - European Journal of Vascular Medicine, 2018, 47, 77-89.	1.4	15

#	ARTICLE	IF	CITATIONS
1124	Epidemiology, Prevention, Diagnosis, and Management of Venous Thromboembolism in Gastrointestinal Cancers. Digestive Disease Interventions, 2020, 04, 248-259.	0.2	1
1125	Prediction of Symptomatic Venous Thromboembolism in Critically Ill Patients: The ICU-Venous Thromboembolism Score*. Critical Care Medicine, 2020, 48, e470-e479.	0.9	19
1126	Venous thromboembolism in patients with cholangiocarcinoma. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	1.6	16
1127	Cortical blindness due to cerebral infarct in advanced pancreatic cancer. BMJ Case Reports, 2019, 12, e223843.	0.5	1
1128	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. ESMO Open, 2020, 5, e000647.	4.5	4
1129	Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer. International Journal of Gynecological Cancer, 2020, 30, 491-497.	2.5	20
1130	New insights into the mechanisms of venous thrombosis. Journal of Clinical Investigation, 2012, 122, 2331-2336.	8.2	322
1131	Development of A Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism In Patients with Cancer-Associated Venous Thromboembolism. Blood, 2010, 116, 475-475.	1.4	9
1132	Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models. Hematology American Society of Hematology Education Program, 2019, 2019, 182-186.	2.5	14
1133	Evaluation of Risk Factors for Venous Thromboembolism in Patients Who Underwent Gynecological Surgery and Validation of a Fast-Rating Assessment Table. Medical Science Monitor, 2019, 25, 8814-8819.	1.1	8
1136	A Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Gastric Cancer Patients: An Inquiry into the Application of Western Guidelines to Asian Cancer Patients. PLoS ONE, 2013, 8, e61968.	2.5	18
1137	Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. PLoS ONE, 2017, 12, e0189410.	2.5	11
1138	Thrombosis and Cancer: Emerging Data for the Practicing Oncologist. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e337-e345.	3.8	9
1139	Retrospective Cohort Study of Venous Thromboembolism Rates in Ambulatory Cancer Patients: Association With Khorana Score and Other Risk Factors. Journal of Hematology (Brossard, Quebec), 2019, 8, 17-25.	1.0	9
1140	Thromboprophylaxis practice patterns and beliefs among physicians treating patients with abdominopelvic cancers at a Canadian centre. Canadian Journal of Surgery, 2020, 63, E562-E568.	1.2	3
1141	Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma. Oncotarget, 2018, 9, 16883-16890.	1.8	25
1142	Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma. Oncotarget, 2018, 9, 21190-21200.	1.8	10
1143	Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. Oncotarget, 2018, 9, 26453-26465.	1.8	35

#	ARTICLE	IF	CITATIONS
1144	PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH CANCER. <i>Atherothrombosis</i> , 2019, 8-24.	0.3	3
1145	Cancer-Associated Thrombosis. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 78-82.	0.3	18
1146	Pancreatic cancer thromboembolic outcomes: rate of thrombosis after adenocarcinoma and non-adenocarcinoma pancreatic cancer surgery. <i>International Angiology</i> , 2019, 38, 194-200.	0.9	3
1147	Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study. <i>International Angiology</i> , 2020, 39, 112-117.	0.9	3
1148	Effect of thromboprophylaxis on the incidence of venous thromboembolism in surgical patients with colorectal cancer: a meta-analysis. <i>International Angiology</i> , 2020, 39, 353-360.	0.9	4
1149	Rate of venous thromboembolism and atrial fibrillation in a real-world case series of advanced cancer patients: the CaTEV Study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 444-452.	1.5	3
1150	Clinical manual for diagnosis, prevention and treatment of cardiovascular complications of cancer therapy. Parts VI-VII. <i>Systemic Hypertension</i> , 2018, 15, 6-20.	0.6	3
1151	Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants. <i>Journal of Korean Medical Science</i> , 2019, 34, e52.	2.5	12
1153	Cardiovascular Complications of Prostate Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 555475.	3.5	14
1154	Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis. <i>Cancers</i> , 2020, 12, 1291.	3.7	18
1155	Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities. <i>Journal of Clinical Medicine</i> , 2020, 9, 1582.	2.4	10
1156	Diretriz Brasileira de Cardio-oncologia 2020. <i>Arquivos Brasileiros De Cardiologia</i> , 2020, 115, 1006-1043.	0.8	37
1158	Venous Thromboembolism in Cancer Patients. <i>Hospital Practice</i> , 2014, 42, 24-33.	0.5	5
1159	Thrombotic risk in cancer patients: Diagnosis and management of venous thromboembolism. <i>Journal of Cardiovascular Echography</i> , 2020, 30, 38.	0.4	3
1160	Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 670-675.	3.0	32
1161	Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism. <i>Cancer Research and Treatment</i> , 2016, 48, 312-321.	3.0	29
1162	Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 866-876.	2.0	13
1163	Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 258.	2.0	18

#	ARTICLE	IF	CITATIONS
1164	Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 176.	2.0	14
1165	Implementing Thrombosis Guidelines in Cancer Patients: A Review. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0041.	1.0	8
1166	Platelets in cancer and thrombosis. <i>Hamostaseologie</i> , 2014, 34, 54-62.	1.9	83
1167	VTE risk assessment in cancer. <i>Phlebologie</i> , 2016, 45, 140-145.	0.3	8
1168	Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2017, 161, 50-53.	0.6	5
1169	Thrombosis in Thyroid Cancer. <i>International Journal of Endocrinology and Metabolism</i> , 2017, 16, e57897.	1.0	11
1170	Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drugâ€Associated Thrombosis Among Patients With Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 840-847.	4.9	101
1171	Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care. <i>Clinics</i> , 2016, 71, 36-46.	1.5	15
1172	Frequency, Clinical Pattern and Outcome of Thrombosis in Cancer Patients in Saudi Arabia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 1311-1315.	1.2	9
1173	Pulmonary embolism in cancer patients. <i>SIRENA register data. Flebologiya</i> , 2021, 15, 179.	1.0	3
1174	Costâ€utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. <i>Cmaj</i> , 2021, 193, E1551-E1560.	2.0	9
1175	Systemic coagulation is activated in patients with meningioma and glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 155, 173-180.	2.9	6
1176	Plasma tumor <scp>DNA</scp> is associated with increased risk of venous thromboembolism in metastatic castrationâ€resistant cancer patients. <i>International Journal of Cancer</i> , 2022, 150, 1166-1173.	5.1	4
1177	Development of a risk score to predict peripherally inserted central catheter thrombosis in active cancer. <i>Internal Medicine Journal</i> , 2022, 52, 1733-1740.	0.8	3
1178	Development and validation of a predictive score for venous thromboembolism in newly diagnosed non-small cell lung cancer. <i>Thrombosis Research</i> , 2021, 208, 45-51.	1.7	8
1179	Risk assessment for recurrent venous thromboembolism in patients with cancer. <i>Thrombosis Update</i> , 2021, 5, 100080.	0.9	5
1180	Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 724682.	2.8	3
1181	Growth differentiation factorâ€15 for prediction of bleeding in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 20, 138.	3.8	8

#	ARTICLE	IF	CITATIONS
1182	Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy. <i>Thrombosis Research</i> , 2021, 208, 71-78.	1.7	14
1183	The incidence of cancer-associated thrombosis is increasing over time. <i>Blood Advances</i> , 2022, 6, 307-320.	5.2	46
1184	Incorporating genetic and clinical data into the prediction of thromboembolism risk in patients with lymphoma. <i>Cancer Medicine</i> , 2021, 10, 7585-7592.	2.8	7
1185	Immune checkpoint inhibitors for cancer and venous thromboembolic events. <i>European Journal of Cancer</i> , 2021, 158, 99-110.	2.8	35
1187	Cancer-Associated Thrombosis~!2009-11-10~!2009-12-11~!2010-02-22~!. <i>Open Cardiovascular Medicine Journal</i> , 2010, 4, 78-82.	0.3	28
1188	Venous Thromboembolism in Patients with Hematologic Malignancies. , 2011, , 449-459.		0
1189	Cancer et Vaisseaux. , 2011, , 493-503.		0
1190	Risk of Thromboembolism with the Angiogenesis inhibitor Bevacizumab in Metastatic Colo-Rectal Cancer Patients. <i>Journal of Korean Society of Health-System Pharmacists</i> , 2011, 28, 1-9.	0.1	0
1191	Venous Thromboembolism in the Cancer Population: Pathology, Risk, and Prevention. <i>Journal of the Advanced Practitioner in Oncology</i> , 2012, 3, .	0.4	5
1192	Are biomarkers useful in thrombotic risk assessment in oncologic patients?. <i>OA Molecular Oncology</i> , 2013, 1, .	0.3	0
1193	The Excessively Clotting Cancer Patient. , 2014, , 161-183.		0
1194	Thrombosen unter besonderen Bedingungen. , 2014, , 335-373.		0
1195	Venous Thromboembolism among Cancer Patients:A Review. , 2014, 21, .		0
1196	Diagnosis, Treatment, and Prevention of Cancer-Associated Venous Thromboembolism. , 2014, , 542-561.e7.		0
1197	Paraneoplastische Gerinnungsst�rungen. , 2015, , 171-180.		0
1198	Prevention of Venous Thromboembolism. , 2015, , 127-149.		0
1199	Cerebral vascular thrombosis in a patient in whom hemodialysis was initiated using a flexible double-lumen (FDL) catheter through the right jugular vein during chemotherapy for intrahepatic bile duct cancer. <i>Nihon Toseki Igakkai Zasshi</i> , 2015, 48, 187-192.	0.1	0
1200	Thrombosis in cancer. <i>Pediatrica I Medycyna Rodzinna</i> , 2015, 11, 48-67.	0.1	2

#	ARTICLE	IF	CITATIONS
1201	THROMBOEMBOLISM IN ONCOLOGY. MODERN VIEW ON THE PROBLEM. Malignant Tumours, 2015, , 172.	0.5	4
1203	Competing Risks Analysis of Cancer-associated Recurrent Thrombosis, Major Bleeds, and Death in a Geriatric Cohort. Journal of Health Economics and Outcomes Research, 2016, 4, 1-18.	1.2	1
1205	Bleeding and Thrombosis in a Cancer Patient. , 2016, , 395-402.		0
1206	Indications for a non-standard use of thromboprophylaxis in patients with ovarian cancer â€“ two case reports and a literature review. Current Gynecologic Oncology, 2016, 14, 53-62.	0.1	0
1207	Ronda cl�nica y epidemiol�gica: club de revistas. Iatreia, 2016, 29, .	0.1	0
1208	Pathologic Aspects of Ischemic Limb Disease. , 2017, , 23-28.		0
1209	Contraception in Malignancies. Majalah Obstetri Dan Ginekologi Indonesia, 0, , .	0.0	0
1210	Pulmoner Emboliye �ncel Yakla��m. Arsiv Kaynak Tarama Dergisi, 2016, 25, 550-570.	0.1	0
1211	In reply: Anticoagulation for atrial fibrillation (January 2017). Cleveland Clinic Journal of Medicine, 2017, 84, 658.2-659.	1.3	0
1212	Cardiac mass: Tumor or thrombus? (July 2017). Cleveland Clinic Journal of Medicine, 2017, 84, 659-659.	1.3	0
1213	Platelets in Deep Venous Thrombosis and Pulmonary Embolism. , 2017, , 1043-1051.		0
1214	Anticoagulation for atrial fibrillation (January 2017). Cleveland Clinic Journal of Medicine, 2017, 84, 658.1-658.	1.3	0
1215	Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status �4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors. Indian Journal of Cancer, 2017, 54, 127.	0.2	1
1217	Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients. Revista Espanola De Enfermedades Digestivas, 2017, 109, 503-509.	0.3	1
1219	Medical scores in clinical practice. Part II. Thromboembolism. Klinicheskaia Meditsina, 2017, 94, 928-931.	0.1	1
1220	Usefulness of Clinical Prediction Rules, D-dimer, and Arterial Blood Gas Analysis to Predict Pulmonary Embolism in Cancer Patients. Oman Medical Journal, 2017, 32, 148-153.	1.0	4
1221	Malignancy-related Venous Thromboembolism of the Distal Leg. The Japanese Journal of Phlebology, 2017, 28, 69-73.	0.0	0
1223	USE OF BEMIPARIN IN PATIENTS UNDERGOING MAJOR SURGERY FOR ESOPHAGEAL AND GASTRIC CANCER. Meditsinskiy Sovet, 2017, , 104-111.	0.5	0

#	ARTICLE	IF	CITATIONS
1224	Resolution of the panel of Expert on Diagnostics, Prevention, and Treatment of Venous Thromboembolism (VTE) in Patients with Malignant Neoplasms. <i>Flebologiya</i> , 2018, 12, 57.	1.0	1
1225	Hemostasis and cancer-associated thrombosis: modern prevention and treatment. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2018, 7, 64.	0.2	3
1228	æ,³æ€Sè...«ç~¼/4^ãĒã,“¼¼%œ–¢é€Łè¡€æ“ç—‡. Japanese Journal of Thrombosis and Hemostasis, 2019, 30, 38-42.	0.1	0
1229	Thromboprophylaxis in Ambulatory Cancer Patients: Results of the AVERT Trial. , 2019, 16, .		0
1230	Gastrointestinal Cancers and Thrombosis. , 2019, , 367-378.		0
1231	Blood coagulation in venous thrombosis, complicating treatment of children, adolescents and young adults with lymphomas. <i>Oncogematologiya</i> , 2019, 13, 37-45.	0.3	0
1232	Evaluation of venous thromboembolic event prophylaxis in hospitalized cancer patients: A single-centered retrospective study. <i>Journal of Research in Pharmacy Practice</i> , 2019, 8, 25.	0.7	0
1233	Critical appraisal of clinical trials in oncology “ part I. <i>Oncology in Clinical Practice</i> , 2019, 15, 89-103.	0.1	1
1234	Minimally Invasive Cardiac Surgery for Left Ventricular Aneurysm with Large Mobile Thrombus Formation after Chemotherapy for Malignant Lymphoma. <i>Japanese Journal of Cardiovascular Surgery</i> , 2019, 48, 316-319.	0.0	0
1235	Rivaroxaban treatment for cancer-associated venous thromboembolism in a patient with heparin-induced thrombocytopenia: a case report. <i>Translational Cancer Research</i> , 2019, 8, 2481-2484.	1.0	1
1236	Vascular Toxicity in Patients with Cancer: Is There a Recipe to Clarify Treatment?<sup>CME</sup>. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 289.	1.0	0
1237	Tissue factor expression predicts outcome in children with neuroblastoma: A retrospective study. <i>Oncology Letters</i> , 2019, 18, 6347-6354.	1.8	5
1239	Cancer-Associated Thrombosis (CAT). , 2020, , 127-145.		0
1240	Thrombophilie, thromboembolische Erkrankungen und antithrombotische Therapie. , 2020, , 1121-1145.		0
1241	4 cases that various thrombosis developed in during head and neck cancer treatment. <i>Japanese Journal of Head and Neck Cancer</i> , 2020, 46, 41-45.	0.1	0
1243	Anticoagulants oraux directs dans la maladie thromboembolique veineuse associée aux cancers. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2020, 2020, 2-8.	0.0	0
1244	The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 286-295.	0.8	2
1246	Follicular lymphoma. <i>Journal of Modern Oncology</i> , 2020, 22, 34-51.	0.3	4

#	ARTICLE	IF	CITATIONS
1247	Revisión sistemática y metanálisis del tratamiento anticoagulante en la trombosis asociada al cáncer. Implicaciones en estudios de no inferioridad. <i>Investigacion Clinica</i> , 2020, 61, 165-180.	0.0	0
1248	Incidence and risk of venous thromboembolism according to primary treatment type in women with endometrial cancer: a population-based study. <i>BMC Cancer</i> , 2021, 21, 1166.	2.6	3
1249	Deep Vein Thrombosis Revealing Prostate Cancer about a Case in the Cardiology Department of the Ignace Deen National Hospital in Conakry. <i>World Journal of Cardiovascular Diseases</i> , 2020, 10, 608-613.	0.2	0
1251	Towards biomarkers for outcomes after pancreatic ductal adenocarcinoma and ischaemic stroke, with focus on (co)-morbidity and ageing/cellular senescence (SASKit): protocol for a prospective cohort study. <i>BMJ Open</i> , 2020, 10, e039560.	1.9	5
1253	Thromboembolic Events in Patients with Testicular Germ Cell Tumours Are Predominantly Triggered by Advanced Disease and by Central Venous Access Systems. <i>Urologia Internationalis</i> , 2021, 105, 257-263.	1.3	5
1254	Point-of-Care Ultrasound for Oncologic Critical Care. , 2020, , 1579-1596.		0
1255	Gynecologic/Oncology Surgery. , 2020, , 443-456.		0
1256	Venous thromboembolic complications in lymphoma patients. <i>Medicinski Podmladak</i> , 2020, 71, 25-39.	0.0	0
1257	Venous thrombosis in pediatric cancer (literature review). <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2020, 6, 69-75.	0.3	0
1258	Progress on the Study and Practice of Venous Thromboembolism after Operation of Tumor. <i>Journal of Biosciences and Medicines</i> , 2020, 08, 79-87.	0.2	0
1259	Direct Oral Anticoagulant Thromboprophylaxis Trials for Ambulatory Cancer Patients: Guideline Changing, but Are They Practice Changing?. , 2020, 17, .		0
1260	How to read a published clinical trial: A practical guide for clinicians. <i>Avicenna Journal of Medicine</i> , 2020, 10, 68.	0.8	0
1261	Venous Thromboembolism in Patents With Lung Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962097791.	1.7	14
1262	Cancer et thrombose. , 2020, , 334-340.e1.		0
1263	Progress of Comprehensive Nursing on the Prevention of Postoperative DVT of Gynecologic Tumor. <i>Advances in Reproductive Sciences</i> , 2020, 08, 201-208.	0.1	0
1264	Early detection of myocardial damage: A multimodality approach. <i>Journal of Cardiovascular Echography</i> , 2020, 30, 4.	0.4	2
1266	Venous Thromboembolism in Japanese Patients With Pancreatic Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110517.	1.7	4
1267	CASSINI and AVERT “ future role of NOACs for VTE prevention in cancer patients?. <i>Vasa - European Journal of Vascular Medicine</i> , 2020, 49, 247-248.	1.4	0

#	ARTICLE	IF	CITATIONS
1268	A Case of Cancer-associated Thrombosis (CAT) Due to Endometrial Cancer Discovered by Lower Leg Edema. The Japanese Journal of Phlebology, 2020, 31, 35-38.	0.0	0
1269	Validation of the Khorana Score to Assess Venous Thromboembolism and Its Association with Mortality in Cancer Patients: A Retrospective Community-based Observational Experience. Cureus, 2020, 12, e7883.	0.5	5
1270	Advances in the Prediction and Risk Assessment of Lung Cancer-Associated Venous Thromboembolism. Cancer Management and Research, 2021, Volume 13, 8317-8327.	1.9	7
1271	Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Pharmacology, 2021, 12, 747075.	3.5	3
1272	Pulmonary Embolism in the Intensive Care Unit: Therapy in Subpopulations. Critical Care Clinics, 2020, 36, 547-560.	2.6	4
1273	Characteristics of Symptomatic Axillary Vein Thrombosis After Placement of Totally Implanted Venous Access Port in Cancer Patients. Iranian Journal of Radiology, 2020, 17, .	0.2	0
1274	EFFECT OF CISPLATIN ON HEMOSTASIS IN EXPERIMENTAL ANIMALS. Siberian Journal of Oncology, 2020, 19, 109-115.	0.3	1
1275	The possibilities of using new (direct) oral anticoagulants in oncology. Onkologie (Czech Republic), 2020, 14, 172-177.	0.1	0
1276	Clinicopathological Characteristics of Cancer-associated Venous Thromboembolism (CAT-VTE) from a Medicolegal Autopsy. The Japanese Journal of Phlebology, 2020, 31, 123-129.	0.0	0
1277	Profilaxis de la enfermedad tromboembólica venosa en pacientes con cáncer. Revista Clinica Espanola, 2020, 220, 17-24.	0.6	3
1279	Venous thromboembolism in the cancer population: pathology, risk, and prevention. Journal of the Advanced Practitioner in Oncology, 2012, 3, 23-33.	0.4	8
1280	Stroke and Cancer- A Complicated Relationship. , 2014, 2, 1039.		45
1281	Management of Venous Thromboembolism for Patients With Hematologic Malignancies. Journal of the Advanced Practitioner in Oncology, 2017, 8, 297-302.	0.4	1
1286	The Incidence of Deep Vein Thrombosis in Breast Cancer Patients Receiving Outpatient Cancer Therapy in Iran. Tanaffos, 2019, 18, 244-253.	0.5	1
1287	Correspondence to: Management of Venous Thromboembolisms: Part II. The Consensus for Pulmonary Embolism and Updates. Acta Cardiologica Sinica, 2021, 37, 213-214.	0.2	0
1289	Gerinnung. , 2022, , 77-83.		0
1290	Factor Xa inhibitors versus low molecular weight heparin for the treatment of cancer associated venous thromboembolism; A meta-analysis of randomized controlled trials and non-randomized studies. Critical Reviews in Oncology/Hematology, 2022, 169, 103526.	4.4	6
1291	Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHHâ€“SETH. Clinical and Translational Oncology, 2022, 24, 770-783.	2.4	1

#	ARTICLE	IF	CITATIONS
1292	Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol. <i>BMJ Open</i> , 2021, 11, e055322.	1.9	3
1293	Pulmonary Embolism in Cancer Patients. , 2022, , 223-233.		0
1294	Variation of platelet function in clinical phenotypes of acute venous thromboembolism â€œ Results from the GMPâ€œVTE project. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 705-715.	3.8	3
1295	Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer. <i>Thrombosis Journal</i> , 2021, 19, 95.	2.1	7
1296	Direct oral anticoagulants in the treatment of venous thromboembolic disease associated with cancer. Evidence and recommendations. <i>Angiologia</i> , 2021, , .	0.0	0
1298	Particulars of anticoagulation in patiens with cancer. <i>Medic Ro</i> , 2021, 5, 48.	0.0	0
1299	Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12634.	2.3	16
1301	Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors. <i>Current Problems in Cancer</i> , 2022, 46, 100832.	2.0	2
1302	A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. <i>Cancers</i> , 2022, 14, 559.	3.7	10
1304	Characteristics of patients with active cancer and venous thromboembolic complications receiving a chemotherapy treatment cycle (according to the â€œreal-lifeâ€œ™ clinical practice of Publicly Funded Health) <i>Tj ETQq1,1 0.784314 rgBT /</i> Atherothrombosis, 2022, 11, 44-54.	0.3	1
1305	Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. <i>Blood Advances</i> , 2022, 6, 2967-2976.	5.2	23
1306	Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial. <i>Thrombosis Research</i> , 2022, 211, 85-87.	1.7	3
1307	A case of carcinoma of the lower gingiva with thrombosis in the flap at the collection of the vascularized fibular flap and postoperative subendocardial infarction. <i>Oral and Maxillofacial Surgery Cases</i> , 2022, 8, 100245.	0.4	1
1308	Endovascular Management of Venous Thromboembolic Disease in the Oncologic Patient Population. <i>Current Oncology Reports</i> , 2022, 24, 351.	4.0	5
1309	Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A <sc>SEERâ€œMedicare</sc> analysis. <i>Cancer Medicine</i> , 2022, 11, 1817-1826.	2.8	6
1310	Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study. <i>Annals of Hematology</i> , 2022, 101, 855-867.	1.8	19
1311	Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 336-343.	4.9	6
1312	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	3.9	17

#	ARTICLE	IF	CITATIONS
1313	Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer. <i>Cancer Medicine</i> , 2022, 11, 1605-1616.	2.8	8
1314	Venous thromboembolism in amyotrophic lateral sclerosis. A prospective quasi-experimental study. <i>Thrombosis Research</i> , 2022, 211, 81-84.	1.7	3
1315	Construction of Risk Assessment Model for Venous Thromboembolism After Colorectal Cancer Surgery: A Chinese Single-Center Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110737.	1.7	7
1316	Venous Thromboembolism in Patients with Gastrointestinal Cancers. <i>Journal of the Japanese Association of Rural Medicine</i> , 2022, 70, 479-484.	0.0	0
1317	Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence. <i>European Journal of Internal Medicine</i> , 2022, 100, 33-45.	2.2	8
1318	Provider education program on the Khorana score to promote venous thromboembolism chemoprophylaxis in patients with gynecologic cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 547-552.	2.5	0
1319	Racial disparities in cancer-associated thrombosis. <i>Blood Advances</i> , 2022, 6, 3167-3177.	5.2	14
1320	Venous thromboembolism and radiation therapy: The final <scp>radiation-induced</scp> thrombosis study analysis. <i>Cancer Medicine</i> , 2022, 11, 1753-1762.	2.8	13
1321	Cancer-associated venous thromboembolism. <i>Nature Reviews Disease Primers</i> , 2022, 8, 11.	30.5	130
1322	Evaluation of the Khorana Predictive Thrombotic Risk and Thromboprophylaxis Score in Cancer Patients in a Third Level Hospital. <i>Open Respiratory Archives</i> , 2022, , .	0.1	0
1323	Prediction models for venous thromboembolism in ambulatory adults with pancreatic and gastro-oesophageal cancer: protocol for systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e056431.	1.9	1
1324	Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel. <i>PLoS ONE</i> , 2022, 17, e0264653.	2.5	5
1326	Microparticles and D-dimers improve prediction of chemotherapy-associated thrombosis in cancer patients. <i>Journal of Ideas in Health</i> , 2022, 5, 637-642.	0.3	0
1327	Incidence, Timing, and Outcomes of Venous Thromboembolism in Patients Undergoing Surgery for Esophagogastric Cancer: A Population-Based Cohort Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 4393-4404.	1.5	10
1328	Venous thromboembolism risk assessment of surgical patients in Southwest China using real-world data: establishment and evaluation of an improved venous thromboembolism risk model. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 59.	3.0	3
1329	External validation of the <scp>HIGH-LOW</scp> model: A predictive score for venous thromboembolism after allogeneic transplant. <i>American Journal of Hematology</i> , 2022, 97, 740-748.	4.1	1
1330	Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). <i>Eurasian Heart Journal</i> , 2022, , 6-79.	0.8	6
1331	Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001056.	1.6	40

#	ARTICLE	IF	CITATIONS
1332	Iron Deficiency is Associated With Platelet Count Elevation in Patients With Dialysis-dependent Chronic Kidney Disease. , 2022, 32, 587-594.		4
1333	Growth Differentiation Factor-15, High-Sensitivity Cardiac Troponin T, and N-Terminal pro-B-type Natriuretic Peptide for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy. Thrombosis and Haemostasis, 2022, 122, 1169-1176.	3.4	4
1334	Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. Clinical and Experimental Medicine, 2023, 23, 313-331.	3.6	21
1335	A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study. Journal of Hematology and Oncology, 2022, 15, 40.	17.0	11
1337	Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors. Journal of Thrombosis and Thrombolysis, 2022, 54, 287-294.	2.1	8
1338	Venous thromboembolism and associated health care utilization in elderly patients with diffuse large B cell lymphoma. Cancer, 2022, , .	4.1	0
1339	Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis. Thrombosis Research, 2022, 213, 47-56.	1.7	4
1340	Evaluating the Khorana risk score of gastrointestinal cancer patients during initial chemotherapy as a predictor of patient mortality: A retrospective study. Journal of Cardiology, 2022, 79, 655-663.	1.9	4
1341	A new pre-test probability score for diagnosis of deep vein thrombosis in patients before surgery. Journal of Cardiology, 2022, 79, 664-670.	1.9	4
1342	Machine learning predicts cancer-associated deep vein thrombosis using clinically available variables. International Journal of Medical Informatics, 2022, 161, 104733.	3.3	17
1343	AHPBA guidelines for managing VTE prophylaxis and anticoagulation for pancreatic surgery. Hpb, 2022, 24, 575-585.	0.3	10
1344	Editorial Comment to Incidence and location of perioperative deep vein thrombosis in patients with bladder cancer undergoing radical cystectomy. International Journal of Urology, 2022, 29, 264-265.	1.0	0
1345	Publisher note. Thrombosis Research, 2021, 208, 173-175.	1.7	2
1346	Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1181-1201.	4.9	43
1347	Cancer thrombosis: Narrative review. Cancer Research Statistics and Treatment, 2020, 3, 501.	0.6	1
1349	Incidence and Determinants of Chemotherapy Associated Thromboembolic Events among Ethiopian Patients Treated for Solid Malignancy: A Retrospective Cross-Sectional Study. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210912.	1.7	1
1350	Immune Checkpoint Inhibitors and Venous Thromboembolism: An Analysis of the WHO Pharmacovigilance Database. Clinical Pharmacology and Therapeutics, 2022, 112, 164-170.	4.7	2
1351	ABO blood group type and risk of venous thromboembolism in patients with cancer. Blood Advances, 2022, 6, 6274-6281.	5.2	17

#	ARTICLE	IF	CITATIONS
1352	Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma. <i>Supportive Care in Cancer</i> , 2022, , 1.	2.2	2
1353	Issue of predicting the risk of thromboembolic complications in patients with lymphoproliferative diseases. <i>Oncogematologiya</i> , 2022, 17, 134-140.	0.3	0
1354	Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 653-659.	1.7	1
1355	Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study. <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	1.3	0
1359	Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1665-1673.	3.8	16
1360	Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients. <i>Tumori</i> , 2012, 98, 594-600.	1.1	7
1366	Thromboembolism and pancreatic cancer. <i>JOP: Journal of the Pancreas</i> , 2014, 15, 292-4.	1.5	1
1368	Thromboembolic Events Burden in Patients With Solid Tumors and Their Predisposing Factors. <i>Cureus</i> , 2022, 14, e23624.	0.5	0
1369	Epidemiological, Clinical and Therapeutic Patterns of Venous Thromboembolic Disease in Cancer Patients Followed up in Two Reference Hospitals in Cameroon. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 250-257.	0.2	0
1370	Venous Thromboembolism In Cancer Patients: “From Evidence to Care” Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210987.	1.7	2
1371	Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline 2022. <i>Physical Therapy</i> , 2022, 102, .	2.4	6
1372	Romiplostim for chemotherapy-induced thrombocytopenia: Efficacy and safety of extended use. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12701.	2.3	6
1373	Anticoagulation in cancer patients; new recommendations based on randomized clinical trials. <i>Vnitřní Lekarství</i> , 2022, 68, 111-115.	0.2	0
1374	Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2125.	3.7	7
1375	Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data. <i>Scientific Reports</i> , 2022, 12, 7646.	3.3	1
1376	Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 381.e1-381.e7.	1.6	4
1377	A Systematic Review of the Guidelines on Venous Thromboembolism Prophylaxis in Gynecologic Oncology. <i>Cancers</i> , 2022, 14, 2439.	3.7	4
1378	Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?. <i>Supportive Care in Cancer</i> , 2022, , .	2.2	0

#	ARTICLE	IF	CITATIONS
1379	Awareness of cancer-associated thrombosis in healthcare providers.. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2022, 32, 325-330.	0.5	0
1380	S'orienter à l'avenir la thrombose : Sensibiliser les professionnels de la santé à la thrombose liée au cancer.. Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique, 2022, 32, 331-336.	0.5	0
1381	Neutrophil extracellular traps and cancer-associated thrombosis. Thrombosis Research, 2022, 213, S35-S41.	1.7	11
1382	Cancer-associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	1
1383	Cancer genetic alterations and risk of venous thromboembolism. Thrombosis Research, 2022, 213, S29-S34.	1.7	3
1384	Building a CAT clinic - real-world systems approaches to prevention and treatment. Thrombosis Research, 2022, 213, S84-S86.	1.7	0
1385	Old is new again: Emergence of thromboembolic complications in cancer patients on immunotherapy. Thrombosis Research, 2022, 213, S51-S57.	1.7	6
1386	Standardization of risk prediction model reporting in cancer-associated thrombosis: Communication from the ISTH SSC subcommittee on hemostasis and malignancy. Journal of Thrombosis and Haemostasis, 2022, 20, 1920-1927.	3.8	3
1387	Clinicopathological Characteristics of Cancer-Associated Venous Thromboembolism (CAT-VTE) from a Medicolegal Autopsy. Annals of Vascular Diseases, 2022, , .	0.5	0
1388	A review of latest clinical practice guidelines for the management of cancer-associated thrombosis. Best Practice and Research in Clinical Haematology, 2022, 35, 101348.	1.7	3
1389	Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations. American Journal of Hematology, 2022, 97, 1044-1054.	4.1	8
1390	Risk assessment and primary prevention of VTE in patients with cancer: Advances, challenges, and evidence gaps. Best Practice and Research in Clinical Haematology, 2022, 35, 101347.	1.7	3
1391	Hemostasis and tumor immunity. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12728.	2.3	7
1392	A Nomogram for Predicting Survival in Patients With Colorectal Cancer Incorporating Cardiovascular Comorbidities. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	3
1393	Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms. Thrombosis Research, 2022, 213, S95-S102.	1.7	9
1394	Venous thromboembolism and risk stratification in hematological malignancies. Thrombosis Research, 2022, 213, S16-S21.	1.7	2
1395	A survey of physician perception and practices regarding pharmacological thromboprophylaxis during chemotherapy for bladder cancer. Canadian Urological Association Journal, 2022, 16, .	0.6	0
1396	Contemporary breast cancer treatment-associated thrombosis. Thrombosis Research, 2022, 213, S8-S15.	1.7	2

#	ARTICLE	IF	CITATIONS
1397	Characteristics and Predictors of Venous Thromboembolism Among Lymphoma Patients Undergoing Chemotherapy: A Cohort Study in China. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
1398	Canadian Urological Association consensus guideline: Management of testicular germ cell cancer. <i>Canadian Urological Association Journal</i> , 2022, 16, 155-73.	0.6	9
1399	Inpatient primary prophylaxis of cancer-associated thromboembolism (CAT). <i>Supportive Care in Cancer</i> , 0, , .	2.2	0
1400	Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study). <i>Cancers</i> , 2022, 14, 2771.	3.7	4
1401	Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting. <i>Best Practice and Research in Clinical Haematology</i> , 2022, , 101351.	1.7	0
1402	Thromboembolic disease prevention before cancer therapy. , 2023, , 92-99.		0
1403	Prevention of VTE after initial presentation and cancer treatment. , 2023, , 271-279.		0
1406	Thrombosis and bleeding in hematological malignancy. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101353.	1.7	7
1407	Prevention and treatment of cancer associated venous thromboembolism - interdisciplinary consensus. <i>Vnitřní Lekarství</i> , 2022, 68, 221-226.	0.2	0
1408	Update on Guidelines for the Prevention of Cancer-Associated Thrombosis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, , 1-8.	4.9	6
1409	The relationship between depressive symptoms and BMI: 2005â€“2018 NHANES data. <i>Journal of Affective Disorders</i> , 2022, 313, 151-157.	4.1	16
1410	Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA2DS2VASC score: CCHA2DS2VASC score. <i>IJC Heart and Vasculature</i> , 2022, 41, 101072.	1.1	5
1411	Venous thromboembolic prophylaxis. , 2022, , 161-175.		0
1412	Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1757-1766.	3.4	6
1413	Thromboprophylaxis in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2807-2815.	1.3	1
1414	Risk of venous thromboembolism in patients with pancreatic cancer. <i>Siberian Journal of Oncology</i> , 2022, 21, 24-32.	0.3	0
1415	Thrombotic complications in patients with cancer: Advances in pathogenesis, prevention, and treatmentâ€“A report from ICTHIC 2021. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12744.	2.3	4
1416	Hyperlipidemia as a risk factor for Trousseau syndromeâ€“related cerebral infarction in patients with advanced gastrointestinal cancer. <i>Oncology Letters</i> , 2022, 24, .	1.8	2

#	ARTICLE	IF	CITATIONS
1417	Chemotherapy Port Induced SVC Thrombosis in a patient with non-Metastatic Breast Cancer. Journal of Community Hospital Internal Medicine Perspectives, 2022, 12, 67-70.	0.8	0
1418	Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendationsâ€“State-of-the-Art. Anticancer Research, 2022, 42, 3261-3274.	1.1	5
1420	Venous thromboembolism risk factors and practices of prophylaxis: ENDORSE study results in Portugal.. Acta Medica Portuguesa, 2012, 24, 951-60.	0.4	9
1421	Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an <i>ad hoc&/i> expert panel. Haematologica, 2022, 107, 2536-2547.	3.5	15
1422	In-hospital prognosis of malignancy-related pulmonary embolism: an analysis of the national inpatient sample 2016â€“2018. Journal of Thrombosis and Thrombolysis, 2022, 54, 630-638.	2.1	4
1423	Retrospective Cohort Analysis of Aspirin Use and Venous Thromboembolism in Patients with Pancreatic Cancer and an Indwelling Central Venous Catheter. TH Open, 2022, 06, e221-e229.	1.4	2
1424	Development and validation of a prediction model of catheter-related thrombosis in patients with cancer undergoing chemotherapy based on ultrasonography results and clinical information. Journal of Thrombosis and Thrombolysis, 2022, 54, 480-491.	2.1	1
1425	Development and validation of a machine learning model to predict venous thromboembolism among hospitalized cancer patients. Asia-Pacific Journal of Oncology Nursing, 2022, 9, 100128.	1.6	7
1426	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal Cardiovascular Imaging, 2022, 23, e333-e465.	1.2	97
1427	The Efficacy of the Systemic Immune-Inflammation Index and Prognosis Nutritional Index for the Diagnosis of Venous Thromboembolism in Gastrointestinal Cancers. Journal of Inflammation Research, 0, Volume 15, 4649-4661.	3.5	4
1428	Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis. European Journal of Internal Medicine, 2022, 105, 30-37.	2.2	9
1429	One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Lung Cancer Patients (Cancer-VTE Subanalysis). JTO Clinical and Research Reports, 2022, , 100392.	1.1	2
1430	The Diagnostic Value of the Systemic Immune-Inflammation Index for Venous Thromboembolism in Lung Cancer Patients: A Retrospective Study. Mediators of Inflammation, 2022, 2022, 1-8.	3.0	5
1431	Antitumor immunity and therapeutic properties of marine seaweeds-derived extracts in the treatment of cancer. Cancer Cell International, 2022, 22, .	4.1	9
1432	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 2022, 43, 4229-4361.	2.2	705
1433	Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study. Current Oncology, 2022, 29, 6077-6090.	2.2	1
1434	Incidental pulmonary embolism in patients with cancer: prevalence, underdiagnosis and evaluation of an AI algorithm for automatic detection of pulmonary embolism. European Radiology, 2023, 33, 1185-1193.	4.5	7
1435	Evaluation of coated platelets, a subset of highly procoagulant platelets, in healthy dogs and dogs with neoplasia. American Journal of Veterinary Research, 2022, 83, .	0.6	0

#	ARTICLE	IF	CITATIONS
1436	Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	2.7	0
1437	Predictive models for thromboembolic events in giant cell arteritis: A US veterans health administration population-based study. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
1439	Precautions When Performing Pericardiocentesis in Patients with Cardiac Tamponade-complicated Malignancy: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2022, , .	0.7	1
1440	Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review. <i>Medicine (United States)</i> , 2022, 101, e29429.	1.0	1
1441	Risk Factors and Risk Stratification of Thromboembolic Risk in Patients with Multiple Myeloma. <i>Hemato</i> , 2022, 3, 518-526.	0.6	0
1442	Preoperative and postoperative clinical signatures of postgastrectomy venous thromboembolism in patients with gastric cancer: A retrospective cohort study. <i>Asian Journal of Surgery</i> , 2023, 46, 1556-1563.	0.4	1
1444	Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research. <i>Targeted Oncology</i> , 2022, 17, 497-505.	3.6	3
1445	Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 0, , .	2.7	2
1446	Pulmonary Embolism in the Cancer Associated Thrombosis Landscape. <i>Journal of Clinical Medicine</i> , 2022, 11, 5650.	2.4	8
1447	Correlation of various platelet indices and its association with susceptibility to develop DVT. <i>Acta Phlebologica</i> , 2022, 23, .	0.3	0
1448	C-reactive protein, immunothrombosis and venous thromboembolism. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	21
1449	The diagnosis and management of suspected lymphoma in general practice. <i>European Journal of Haematology</i> , 2023, 110, 3-13.	2.2	1
1450	Deep Venous Thrombosis. <i>Annals of Internal Medicine</i> , 2022, 175, ITC129-ITC144.	3.9	31
1451	The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2921-2929.	3.8	5
1452	Direct Oral Anti-Coagulants Continue to Bud into Gynecological Cancer-Thrombosis Prevention. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211337.	1.7	0
1454	Epidemiology and prevention of venous thromboembolism. <i>Nature Reviews Cardiology</i> , 2023, 20, 248-262.	13.7	52
1456	Mitigating acute chemotherapy-associated adverse events in patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 681-697.	27.6	26
1457	Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	5.0	1

#	ARTICLE	IF	CITATIONS
1458	Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis. <i>Vascular Health and Risk Management</i> , 0, Volume 18, 793-807.	2.3	2
1459	Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
1460	Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patients' and Clinicians' Awareness. <i>Life</i> , 2022, 12, 1594.	2.4	3
1461	Primary thromboprophylaxis and the risk of venous thromboembolic events in patients with testicular germ cell tumors treated with cisplatin-based chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	0
1462	Cabozantinib safety with different anticoagulants in patients with renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1
1463	Challenges in managing patients on anticoagulation: Thrombocytopenia, resumption after bleeding and recurrent thrombosis. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2022, 52, 341-349.	0.6	1
1464	Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience. <i>Cancers</i> , 2022, 14, 5640.	3.7	7
1466	Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data. <i>International Journal of Clinical Oncology</i> , 2023, 28, 69-78.	2.2	6
1467	Oral Squamous Cell Carcinoma-Associated Thrombosis: What Evidence?. <i>Cancers</i> , 2022, 14, 5616.	3.7	1
1468	Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma. <i>JACC: CardioOncology</i> , 2022, 4, 522-531.	4.0	12
1469	Using the Khorana risk score to predict venous thromboembolism and overall survival in a cohort of Hispanic patients with solid malignancies. <i>Ecancermedicalscience</i> , 0, 16, .	1.1	1
1470	Determining venous thromboembolism risk in patients with adult-type diffuse glioma. <i>Blood</i> , 2023, 141, 1322-1336.	1.4	3
1471	Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembolism; a cohort study. <i>Thrombosis Research</i> , 2023, 221, 10-18.	1.7	3
1472	Risk of venous thromboembolism and major bleeding in the clinical course of osteosarcoma and Ewing sarcoma. <i>Thrombosis Research</i> , 2023, 221, 19-25.	1.7	4
1473	Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative. <i>Gynecologic Oncology</i> , 2023, 168, 144-150.	1.4	2
1474	Preoperative coagulation biomarkers associate with survival and pulmonary embolism after surgical treatment of non-spinal skeletal metastases. <i>Thrombosis Journal</i> , 2022, 20, .	2.1	0
1475	Prophylaxe venöser Thromboembolien in der nicht-operativen Medizin. <i>Springer Reference Medizin</i> , 2023, , 1-6.	0.0	0
1476	Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 6216.	3.7	6

#	ARTICLE	IF	CITATIONS
1478	Bridging therapy according to new clinical guidelines: A review. Consilium Medicum, 2022, 24, 703-712.	0.3	0
1479	Postoperative Venous Thromboembolism Risk Stratification in Patients with Uterine Cancer.. American Journal of Obstetrics and Gynecology, 2022, , .	1.3	0
1480	The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study. TH Open, 2023, 07, e14-e29.	1.4	0
1481	Derivation and Validation of a Clinical Risk Assessment Model for Cancer-Associated Thrombosis in Two Unique US Health Care Systems. Journal of Clinical Oncology, 2023, 41, 2926-2938.	1.6	11
1482	Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study. Current Oncology, 2023, 30, 1032-1045.	2.2	1
1483	Ảĩc Ảĩá»fm Ảĩm sẢĩng, cáĩn Ảĩm sẢĩng, tá» lá»† tá»-vong á»Ỗ bá»ĩnh nhẢĩn táĩc Ảĩá»™ng má»ĩch phá»i cá»p kẢĩm ung thẢĩ. Tạp chí Y học Việt Nam, 2023, 160, 61-68.	0.0	0
1484	Anemia and formation of deep vein thrombosis before operation in patients with knee osteoarthritis: a cross-sectional study. Journal of Orthopaedic Surgery and Research, 2023, 18, .	2.3	2
1486	Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence. Journal of Thrombosis and Haemostasis, 2023, 21, 758-770.	3.8	1
1487	Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer. Atherothrombosis, 2023, 12, 44-62.	0.3	0
1488	Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer. , 2023, 11, e006072.		12
1489	Treatment and prevention of cancer-associated thrombosis in the Netherlands: A national survey. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100057.	2.3	2
1490	Venous Thromboembolism in Japanese Patients with Gynecologic Cancer. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 107602962211241.	1.7	0
1491	Survey of medical oncologists and trainee practice on venous thromboembolism prophylaxis and treatment in solid cancers. Internal Medicine Journal, 2023, 53, 131-135.	0.8	1
1492	Risk and timing of venous thromboembolism in patients with gastrointestinal cancer: a nationwide Danish cohort study. BMJ Open, 2023, 13, e062768.	1.9	3
1493	Prophylactic Anticoagulation in Patients with Cancer: When and How?. Current Oncology Reports, 2023, 25, 201-209.	4.0	2
1494	Prevalence of Cancer in Patients with Venous Thromboembolism: A Retrospective Nationwide Case-Control Study in Sweden. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, 107602962311583.	1.7	2
1495	Using machine learning to predict venous thromboembolism and major bleeding events following total joint arthroplasty. Scientific Reports, 2023, 13, .	3.3	7
1496	Unreported incidental pulmonary embolism in patients with cancer: Radiologic natural history and risk of recurrent venous thromboembolism and death. Thrombosis Research, 2023, 224, 65-72.	1.7	2

#	ARTICLE	IF	CITATIONS
1497	Arterial and Venous Thromboembolism in <i>ALK</i> -Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study. <i>Oncologist</i> , 0, , .	3.7	0
1498	Prognostic Value of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Predicting Venous Thromboembolism in Children With Lymphoma. <i>Circulation: Cardiovascular Imaging</i> , 0, , .	2.6	0
1499	Assessing the need for venous thromboembolism prophylaxis at the time of neoadjuvant chemotherapy for ovarian cancer: A literature review. <i>Gynecologic Oncology</i> , 2023, 170, 167-171.	1.4	3
1500	Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 294-302.	3.8	5
1501	The Kagoshima-DVT Score Is a Useful Predictive Model for Cancer-Associated Thrombosis in Patients With Gastrointestinal Cancer. <i>Circulation Reports</i> , 2023, 5, 19-26.	1.0	0
1502	Approaches for optimizing venous thromboembolism prevention in injured patients: Findings from the consensus conference to implement optimal venous thromboembolism prophylaxis in trauma. <i>Journal of Trauma and Acute Care Surgery</i> , 2023, 94, 469-478.	2.1	14
1503	A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 2911-2925.	1.6	13
1504	A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3169.	4.1	32
1505	Precautions during Direct Oral Anticoagulant Introduction in Gynecologic Malignancies: A Single-Center Retrospective Cohort Study. <i>Cancers</i> , 2023, 15, 1132.	3.7	0
1506	Apixaban for Extended Thromboprophylaxis After Oncologic Resection: Outcomes and Cost Analysis. <i>American Surgeon</i> , 2023, 89, 5428-5435.	0.8	0
1507	Incidental right atrial mass in a patient with secondary pancreatic cancer: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 0, 11, 1206-1216.	0.8	0
1508	Development and validation of machine learning models for postoperative venous thromboembolism prediction in colorectal cancer inpatients: a retrospective study. <i>Journal of Gastrointestinal Oncology</i> , 2023, 14, 220-232.	1.4	2
1509	Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer. <i>JAMA Network Open</i> , 2023, 6, e230010.	5.9	6
1510	VTE epidemiology and challenges for VTE prevention at the population level. <i>Thrombosis Update</i> , 2023, 10, 100132.	0.9	4
1511	Perioperative Anticoagulation in Patients with Cancer. <i>Current Oncology Reports</i> , 2023, 25, 379-386.	4.0	0
1512	Increased In Vivo Thrombin Generation in Patients with Localized Non-Small Cell Lung Cancer Unfit for Surgery. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 107602962311528.	1.7	2
1513	Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer. <i>Gynecologic Oncology Reports</i> , 2023, 46, 101156.	0.6	3
1514	Risk factors for totally implantable access ports-associated thrombosis in pediatric oncology patients. <i>Scientific Reports</i> , 2023, 13, .	3.3	0

#	ARTICLE	IF	CITATIONS
1515	Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment. Current Oncology Reports, 2023, 25, 445-454.	4.0	0
1516	Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management. Current Oncology, 2023, 30, 3032-3046.	2.2	9
1517	Oncologic Emergencies in Patients Undergoing Major Surgery. , 2023, , 125-134.		0
1518	Cardiovascular Side Effects of Anthracyclines and HER2 Inhibitors among Patients with Breast Cancer: A Multidisciplinary Stepwise Approach for Prevention, Early Detection, and Treatment. Journal of Clinical Medicine, 2023, 12, 2121.	2.4	3
1519	Impact of body mass index on venous thromboembolism recurrence with direct oral anticoagulants. American Journal of Emergency Medicine, 2023, 67, 187-188.	1.6	1
1520	Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. Journal of Thrombosis and Haemostasis, 2023, 21, 1397-1408.	3.8	7
1521	Platelet Parameters as Biomarkers for Thrombosis Risk in Cancer: A Systematic Review and Meta-analysis. Seminars in Thrombosis and Hemostasis, 2024, 50, 360-383.	2.7	1
1522	Meningioma resection and venous thromboembolism incidence, management, and outcomes. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100121.	2.3	1
1523	Summitting thrombotic hazards in glioma. Blood, 2023, 141, 1245-1246.	1.4	0
1524	Usefulness of blood biomarkers for predicting venous thromboembolism in Japanese patients with cancer. Oncology Letters, 2023, 25, .	1.8	1
1525	Venous thromboembolism in metastatic pancreatic cancer. European Journal of Haematology, 2023, 110, 706-714.	2.2	3
1526	Venous Thromboembolism in Patients with Advanced Pancreatic Cancer Receiving Palliative Chemotherapy: Incidence and Effect on Prognosis. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2023, 81, 109-120.	0.4	1
1527	Overview of venous thromboembolism (VTE) in patients with haematological malignancy. Haematology Journal of Bangladesh, 2023, 7, 52-58.	0.1	0
1528	Fine Tuning Venous Thromboembolism Risk Prediction in Patients With Cancer. Journal of Clinical Oncology, 0, , .	1.6	0
1529	Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Anticancer Research, 2023, 43, 1741-1747.	1.1	1
1530	D-dimer testing: A narrative review. Advances in Clinical Chemistry, 2023, , 151-223.	3.7	1
1531	Listeriosis Risk Model for Cancer Patients Who Consume Ready-to-Eat Salad. Journal of Food Protection, 2023, 86, 100087.	1.7	1
1532	Prophylaxe venöser Thromboembolien in der nicht-operativen Medizin. Springer Reference Medizin, 2023, , 1-6.	0.0	0

#	ARTICLE	IF	CITATIONS
1533	Clinical Significance of Venous Thromboembolism in Patients with Advanced Cholangiocarcinoma. Gut and Liver, 2024, 18, 165-173.	2.9	0
1534	Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort. Journal of Thrombosis and Haemostasis, 2023, 21, 1869-1881.	3.8	5
1535	Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review. BMJ Open Respiratory Research, 2023, 10, e001493.	3.0	0
1536	External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center. American Journal of Hematology, 0, , .	4.1	0
1537	Risk Factors for Preoperative Venous Thromboembolism of Ovarian Cancer. Advances in Clinical Medicine, 2023, 13, 5746-5754.	0.0	0
1538	Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro. Cancers, 2023, 15, 2347.	3.7	1
1539	Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges. Current Treatment Options in Oncology, 2023, 24, 693-710.	3.0	4
1540	Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. Neuro-Oncology, 2023, 25, 1381-1394.	1.2	3
1541	Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study. Journal of Thrombosis and Haemostasis, 2023, 21, 2189-2201.	3.8	3
1543	Direct-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review. Cancers, 2023, 15, 2697.	3.7	1
1545	Current Status of Formation and Evaluation of Malignant Tumor Related Venous Thrombosis. Advances in Clinical Medicine, 2023, 13, 7393-7401.	0.0	0
1546	Venous Thrombosis Recurrence After Catheter-Related Upper Extremity Deep Venous Thrombosis in Cancer Patients: A Retrospective Analysis. Angiology, 0, , 000331972311769.	1.8	3
1547	Prevention of venous thromboembolism in patients with cancer. BMJ, The, 0, , e072715.	6.0	2
1548	Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy. Thrombosis Journal, 2023, 21, .	2.1	1
1549	The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience. Cancers, 2023, 15, 3124.	3.7	0
1550	Use of the RCOG risk assessment model and biomarkers to evaluate the risk of postpartum venous thromboembolism. Thrombosis Journal, 2023, 21, .	2.1	0
1551	Applications of Viscoelastic Testing in Breast Cancer Patients: A Systematic Review Focusing on Hypercoagulability and Free Flap Thrombosis. Seminars in Thrombosis and Hemostasis, 2024, 50, 413-422.	2.7	0
1552	Incidence, prevention, risk factors, and prediction of venous thromboembolism in Chinese patients after colorectal cancer surgery: a prospective, multicenter cohort study. International Journal of Surgery, 2023, 109, 3003-3012.	2.7	1

#	ARTICLE	IF	CITATIONS
1554	Prevalence of preoperative asymptomatic deep vein thrombosis in patients undergoing elective general surgery for benign disease. <i>Annals of Gastroenterological Surgery</i> , 2023, 7, 1042-1048.	2.4	0
1556	Role of circulating mitochondria in venous thrombosis in glioblastoma. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2202-2212.	3.8	1
1557	Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study). <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
1558	Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 2461-2472.	3.8	2
1559	Formation Mechanism and Influencing Factors of Venous Thromboembolism Associated with Gastrointestinal Cancer. <i>Advances in Clinical Medicine</i> , 2023, 13, 8026-8033.	0.0	0
1560	Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive. <i>Internal and Emergency Medicine</i> , 2023, 18, 1619-1634.	2.0	2
1561	Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors. <i>British Journal of Cancer</i> , 2023, 129, 309-317.	6.4	9
1562	Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France. <i>Cancers</i> , 2023, 15, 3011.	3.7	2
1563	Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System. <i>JAMA Network Open</i> , 2023, 6, e2317945.	5.9	1
1564	Cancer-associated thrombosis by cancer sites and inherited factors in a prospective population-based cohort. <i>Thrombosis Research</i> , 2023, 229, 69-72.	1.7	2
1565	Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis. <i>Clinical Medicine Insights: Oncology</i> , 2023, 17, .	1.3	3
1566	Considerations for pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies. <i>Brachytherapy</i> , 2023, , .	0.5	0
1567	Risk factors for thromboembolism during first-line treatment of patients with unresectable advanced or recurrent colorectal cancer: a retrospective short study. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2023, 9, .	1.0	0
1568	Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy. <i>Baylor University Medical Center Proceedings</i> , 0, , 1-6.	0.5	0
1569	Current Management of Cancer-Associated Thromboembolism in the Prophylactic and Acute Setting. <i>Current Treatment Options in Cardiovascular Medicine</i> , 0, , .	0.9	0
1570	Is native E coli- or Peg-ASP more thrombogenic in adult ALL? A systematic review and meta-analysis. <i>Thrombosis Update</i> , 2023, 12, 100143.	0.9	0
1571	Comparison among three predictive models for cancer-associated thromboembolism in a hispanic population. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 433-438.	2.1	1
1572	Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care. <i>Cancers</i> , 2023, 15, 3546.	3.7	1

#	ARTICLE	IF	CITATIONS
1573	COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 447-453.	2.1	3
1574	Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?. <i>Gynecologic Oncology</i> , 2023, 176, 36-42.	1.4	7
1575	Predicting venous thromboembolism (VTE) risk in cancer patients using machine learning. , 2023, 2, 205-222.		0
1576	Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice. <i>Current Research in Translational Medicine</i> , 2023, 71, 103405.	1.8	0
1577	High-intensity interval training and thromboembolic events during chemotherapy for testicular cancer: a retrospective analysis from the <i>Body & Cancer</i> cohort. <i>Acta Oncol³gica</i> , 2023, 62, 666-672.	1.8	1
1578	Optimal D-Dimer Cutoff Values for Diagnosing Deep Vein Thrombosis in Patients with Comorbid Malignancies. <i>Annals of Vascular Surgery</i> , 2024, 98, 293-300.	0.9	1
1580	Cancer-associated fibroblasts promote venous thrombosis through podoplanin/CLEC-2 interaction in podoplanin-negative lung cancer mouse model. <i>Journal of Thrombosis and Haemostasis</i> , 2023, 21, 3153-3165.	3.8	2
1581	A nomogram for predicting the risk of venous thromboembolism in patients with solid cancers. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 414-422.	2.1	1
1584	Preoperative D-dimer Value and Lower Limb Venous Ultrasound for Deep Venous Thrombosis Prevents Postoperative Symptomatic Venous Thromboembolism in Patients Undergoing Colorectal Surgery: A Retrospective Study. <i>Journal of the Anus, Rectum and Colon</i> , 2023, 7, 159-167.	1.1	0
1586	Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-Analysis. <i>Cureus</i> , 2023, , .	0.5	0
1587	Thrombosis in multiple myeloma: mechanisms, risk assessment and management. <i>Leukemia and Lymphoma</i> , 2023, 64, 1905-1913.	1.3	2
1588	Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19. <i>JAMA Oncology</i> , 2023, 9, 1390.	7.1	2
1589	Simple yet (more?) effective. Venous thromboembolism risk assessment model for germ cell tumour patients receiving firstâ€line chemotherapy. <i>Cancer Medicine</i> , 2023, 12, 18542-18556.	2.8	0
1590	Venous thromboembolism prevention in cancer care: implementation strategies to address underuse. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102173.	2.3	0
1591	Prediction of Venous Thromboembolism in Patients With Cancer Using Machine Learning Approaches: A Systematic Review and Meta-Analysis. <i>JCO Clinical Cancer Informatics</i> , 2023, , .	2.1	0
1592	Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1â€%â€¥â€%50% advanced non small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 15095-15102.	2.5	1
1593	Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients. <i>Bone Marrow Transplantation</i> , 2023, 58, 1247-1253.	2.4	2
1595	Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study. <i>Gastric Cancer</i> , 0, , .	5.3	0

#	ARTICLE	IF	CITATIONS
1596	A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients. <i>Cancers</i> , 2023, 15, 4588.	3.7	2
1597	The Role of Injectables in the Treatment and Prevention of Cancer-Associated Thrombosis. <i>Cancers</i> , 2023, 15, 4640.	3.7	1
1598	Estimating Venous Thromboembolism Risk in Metastatic Colorectal Cancer Inpatients: Validation of Existing Risk Scores and Development of New Risk Scores. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, .	1.7	1
1599	Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus. <i>Flebologiya</i> , 2023, 17, 152.	1.0	6
1600	Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort. <i>Journal of Gastroenterology</i> , 0, , .	5.1	0
1601	Understanding risks and refining strategies for thromboembolism prophylaxis in hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	0
1602	Early identification of lung cancer patients with venous thromboembolism: development and validation of a risk prediction model. <i>Thrombosis Journal</i> , 2023, 21, .	2.1	0
1603	Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers. <i>JAMA Oncology</i> , 2023, 9, 1536.	7.1	3
1604	ABO Blood Group and the Risk of Thrombosis in Cancer Patients: A Mini-Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 423-428.	2.7	0
1605	Cancer and the risk of perioperative arterial ischaemic events. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 0, , .	4.0	0
1606	Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma. <i>Blood Advances</i> , 0, , .	5.2	0
1607	Validation of venous thromboembolism predictive model in hematologic malignancies. <i>Annals of Hematology</i> , 2023, 102, 3613-3620.	1.8	1
1608	Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2024, 22, 92-97.	1.9	0
1609	Association between the Khorana risk score and all-cause mortality in Japanese patients with gastric and colorectal cancer: A retrospective cohort study. <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 1784-1795.	2.0	0
1610	Thrombin Generation Markers as Predictors of Cancer-Associated Venous Thromboembolism: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 384-401.	2.7	1
1612	Implementation of routine venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer. <i>Gynecologic Oncology</i> , 2023, 178, 89-95.	1.4	3
1613	Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102231.	2.3	1
1615	In Search of the Perfect Thrombosis and Bleeding-Associated Cancer Scale. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 443-454.	2.7	1

#	ARTICLE	IF	CITATIONS
1616	Previous Ischemic Stroke Significantly Alters Stroke Risk in Newly Diagnosed Cancer Patients. <i>Stroke</i> , 2023, 54, 3064-3073.	2.0	0
1617	D-dimer predicts venous thromboembolism in multiple myeloma: a nested case-control study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 102235.	2.3	1
1618	Challenges in Coagulation Management in Neurosurgical Diseases: A Scoping Review, Development, and Implementation of Coagulation Management Strategies. <i>Journal of Clinical Medicine</i> , 2023, 12, 6637.	2.4	0
1619	Thromboembolism during cancer-treatment. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2023, 34, 572-578.	0.1	0
1620	Cancer associated thrombosis in gynecologic cancer. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2023, 34, 579-583.	0.1	0
1621	Management of cancer-associated thrombosis—current status of treatment of cancer-associated venous thromboembolism. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2023, 34, 538-548.	0.1	0
1622	Management of cancer-associated thrombosis—current status of treatment of cancer-associated venous thromboembolism. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2023, 34, 540-555.	0.1	0
1623	What should a general practitioner know about the management of patients with venous thromboembolism?. <i>Klinicist</i> , 2023, 17, 47-54.	0.5	0
1624	Trousseau's Syndrome with Advanced Neuroendocrine Carcinoma of Colon: A Case Report. <i>Case Reports in Oncology</i> , 2023, 16, 490-496.	0.7	2
1625	Development and Validation of a Modified Khorana Score for Predicting Venous Thromboembolism in Newly Diagnosed Stage IV Lung Cancer. <i>Angiology</i> , 2023, 74, 115-122.	1.8	0
1626	Development and Validation of a Clinical Prediction Model for Venous Thromboembolism Following Neurosurgery: A 6-Year, Multicenter, Retrospective and Prospective Diagnostic Cohort Study. <i>Cancers</i> , 2023, 15, 5483.	3.7	0
1627	Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients. <i>Expert Review of Hematology</i> , 2023, 16, 1135-1142.	2.2	0
1628	Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 17771-17780.	2.5	1
1629	Venous Thromboembolism Risk Assessment in Hospitalized Cancer Patients: A Single Center Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2023, 29, 1-10.	1.7	0
1630	Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China. <i>Annals of Medicine</i> , 2023, 55, 1-10.	3.8	0
1631	Use of direct oral anticoagulants in hematologic malignancies. <i>Thrombosis Update</i> , 2023, 13, 100152.	0.9	0
1632	RNA-sequencing to discover genes and signaling pathways associated with venous thromboembolism in glioblastoma patients: A case-control study. <i>Thrombosis Research</i> , 2023, 232, 27-34.	1.7	0
1633	A Predictive Model for Cancer-Associated Thrombosis in Japanese Cancer Patients: Findings from the J-Khorana Registry. <i>TH Open</i> , 2023, 7, 1-10.	1.4	0

#	ARTICLE	IF	CITATIONS
1634	Comparison of risk prediction scores for cancer-associated thrombosis in ambulatory cancer patients not receiving thromboprophylaxis: A prospective cohort study in a South-East Asian population. Thrombosis Research, 2023, 232, 138-144.	1.7	0
1635	VTE prevention in medical inpatients - Current approach and controversies. Thrombosis Update, 2023, 13, 100151.	0.9	0
1636	Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis. Journal of the Chinese Medical Association, 0, , .	1.4	1
1637	Establishment and Validation of a Postoperative VTE Prediction Model in Patients with Colorectal Cancer Undergoing Radical Resection: CRSPOT Nomogram. Clinical and Applied Thrombosis/Hemostasis, 2023, 29, .	1.7	0
1638	Treatment and Prevention of Venous Thromboembolism. , 2023, , 165-176.		0
1639	Development and Validation of a Prediction Model for Venous Thrombus Embolism (VTE) in Patients With Colorectal Cancer. Technology in Cancer Research and Treatment, 2023, 22, .	1.9	1
1640	Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group. Thrombosis Research, 2024, 233, 153-164.	1.7	0
1641	Cellular Components Contributing to the Development of Venous Thrombosis in Patients with Pancreatic Cancer. Seminars in Thrombosis and Hemostasis, 2024, 50, 429-442.	2.7	1
1642	Research Progress on the Prognostic Significance of Neutrophil Platelet Score in Patients with Malignant Tumors. Advances in Clinical Medicine, 2023, 13, 18775-18779.	0.0	0
1643	The association of tumor-expressed REG4, SPINK4 and alpha-1 antitrypsin with cancer-associated thrombosis in colorectal cancer. Journal of Thrombosis and Thrombolysis, 0, , .	2.1	0
1644	Risk Factors and Pathophysiology of Venous Thromboembolism in Patient With Malignancy. , 2023, , .		0
1645	Incidence of venous thromboembolism and predictive ability of age-adjusted international prognostic index for prediction of venous thromboembolism in Asian patients with diffuse large B-cell lymphoma. Journal of Thrombosis and Thrombolysis, 0, , .	2.1	0
1646	Management of adverse reactions during treatment of anal cancer. Onkologie (Czech Republic), 2023, 17, 373-378.	0.1	0
1647	Long Non-Coding RNAs: Bridging Cancer-Associated Thrombosis and Clinical Outcome of Ovarian Cancer Patients. International Journal of Molecular Sciences, 2024, 25, 140.	4.1	0
1648	Development and validation of a nomogram model for predicting the risk of venous thromboembolism in lymphoma patients undergoing chemotherapy: a prospective cohort study conducted in China. Annals of Medicine, 2023, 55, .	3.8	0
1649	Cancer-Associated Thrombosis: Epidemiology, Pathophysiological Mechanisms, Treatment, and Risk Assessment. Clinical Medicine Insights: Oncology, 2023, 17, .	1.3	1
1650	Risk factors for peripherally inserted central catheter-related venous thrombosis in adult patients with cancer. Thrombosis Journal, 2024, 22, .	2.1	0
1651	A systematic review of risk prediction model of venous thromboembolism for patients with lung cancer. Thoracic Cancer, 2024, 15, 277-285.	1.9	0

#	ARTICLE	IF	CITATIONS
1652	Prospective analysis of pre and postoperative laboratory parameters associated with thrombosis in patients with ovarian cancer. Journal of Thrombosis and Thrombolysis, 2024, 57, 492-496.	2.1	0
1653	Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade. Cancers, 2024, 16, 450.	3.7	0
1654	Preoperative laboratory parameters associated with deep vein thrombosis in patients with ovarian cancer: retrospective analysis of 3,147 patients in a single institute. Journal of Gynecologic Oncology, 0, 35, .	2.2	0
1655	A nonneutralizing antibody as cause of prothrombin deficiency in a patient with follicular lymphoma. Clinical Case Reports (discontinued), 2024, 12, .	0.5	0
1656	Models for predicting venous thromboembolism in ambulatory patients with lung cancer: A systematic review and meta-analysis. Thrombosis Research, 2024, 234, 120-133.	1.7	0
1658	The Application of Existing Risk Assessment Models (RAMS) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin Lymphoma. Journal of Clinical Medicine, 2024, 13, 436.	2.4	0
1659	Cancer-Associated Thrombosis and Beyond: Biomarkers, Treatments, and Cancer-Hemostasis Interactions. Seminars in Thrombosis and Hemostasis, 2024, 50, 325-327.	2.7	0
1661	Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer. Journal of Thrombosis and Haemostasis, 2024, 22, 1132-1144.	3.8	0
1662	Novel Insights in Venous Thromboembolism Risk Assessment Methods in Ambulatory Cancer Patients: From the Guidelines to Clinical Practice. Cancers, 2024, 16, 458.	3.7	0
1663	Developing a risk assessment tool for cancer-related venous thrombosis in China: a modified Delphi-analytic hierarchy process study. BMC Cancer, 2024, 24, .	2.6	0
1664	Cancer-associated thrombosis in hematologic malignancies. International Journal of Hematology, 2024, 119, 516-525.	1.6	0
1665	Anticoagulant prescribing patterns in patients with primary central nervous system malignancies and secondary metastases. Journal of Thrombosis and Thrombolysis, 2024, 57, 418-427.	2.1	0
1666	Natural history of cancer-associated splanchnic vein thrombosis. Journal of Thrombosis and Haemostasis, 2024, 22, 1421-1432.	3.8	0
1667	The value of performance status in predicting venous thromboembolism in lung cancer patients treated with immune checkpoint inhibitors. European Journal of Oncology Nursing, 2024, 69, 102527.	2.1	0
1668	Thrombophilie, thromboembolische Erkrankungen und antithrombotische Therapie. , 2024, , 1177-1202.		0
1669	Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database. Gynecologic Oncology, 2024, 185, 116-120.	1.4	0
1670	Cerebral venous sinus thrombosis in a patient treated with ribociclib for metastatic breast cancer. Case reports and literature review. SAGE Open Medical Case Reports, 2024, 12, .	0.3	0
1671	The prognostic role of markers of systemic inflammation in patients with metastatic lung cancer receiving immunotherapy: A comprehensive review of the literature. Pharmacia, 0, 71, 1-7.	1.2	0

#	ARTICLE	IF	CITATIONS
1672	Risk of Venous Thromboembolism by Cancer Type: A Network Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 328-341.	2.7	0
1673	The Conundrum of Cancer-Associated Thrombosis: Lesson Learned from Two Intriguing Cases and Literature Review. <i>Diseases (Basel, Switzerland)</i> , 2024, 12, 47.	2.5	0
1674	The pathogenesis of cancer-associated thrombosis. <i>International Journal of Hematology</i> , 2024, 119, 495-504.	1.6	0
1675	Assessing hypercoagulability and <scp>VTE</scp> risk using thromboelastography and Khorana score in women with cancers receiving chemotherapy. <i>American Journal of Hematology</i> , 2024, 99, .	4.1	0
1676	Incidence of venous thromboembolism in patients with ovarian cancer receiving neoadjuvant chemotherapy: systematic review and meta-analysis. <i>International Journal of Gynecological Cancer</i> , 0, , ijgc-2023-005166.	2.5	0
1677	Using a thrombodynamics test for diagnostics of hypercoagulation and prediction of thromboembolic complications in patients with malignant tumors. <i>Gematologiya I Transfuziologiya</i> , 2024, 69, 20-31.	0.6	0
1679	Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023). <i>Frontiers in Pharmacology</i> , 0, 15, .	3.5	0
1680	Primary Thromboprophylaxis for the Prevention of Venous Thromboembolism in Cancer Patients with Central Venous Catheters: A Literature Review. <i>Journal of Clinical Medicine</i> , 2024, 13, 1660.	2.4	0
1681	Cancer patients and ischemic stroke. <i>Thrombosis Research</i> , 2024, 237, 155-162.	1.7	0
1682	Hydrogel-based drug delivery systems for synergistic chemo/hyperthermia therapy of cancer: A comprehensive review. <i>Journal of Drug Delivery Science and Technology</i> , 2024, 95, 105581.	3.0	0